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ABSTRACT 
 
Alzheimer’s disease (AD) is the most common progressive age related dementia and the 
fourth major cause of mortality in the elderly in the United States.  AD is pathologically 
characterized by deposition of amyloid beta (Aβ) plaques in the brain parenchyma and 
neurofibrillary tangles (NFTs) within the neuronal soma.  While pharmacological targets have 
been discovered, current strategies for the symptomatic or disease-modifying treatment of AD do 
not significantly slow or halt the underlying pathological progression of the disease.  
Consequently, more effective treatment is needed.  One possibility for amelioration is using 
human umbilical cord blood cell (HUCBC) therapy.  HUCBCs comprise a population of 
hematopoietic stem and progenitor cells.  During recent years, functional recovery has been 
observed from the use of HUCBCs in pre-clinical animal models of brain and spinal cord 
injuries.  Thus, modulation by cell therapy, specifically HUCBCs, may be a suitable treatment 
for AD and other models because of the observed cognitive and behavioral improvements.  The 
studies presented in this dissertation centers on the suitability of using HUBCs as a potential 
treatment for AD.  Expanding on this, the aims of the study sought to: (I) Investigate bio-
distribution of HUCBC transplantation in PSAPP mice, (II) Characterize efficacy and determine 
therapeutic outcome of HUCBC following short and long term multi injections at early and late 
disease stages in PSAPP mice and (III) Determine AD-like pathological and cognitive changes 
associated with multiple HUCBC-derived monocyte (CD14) injections in PSAPP mice. Thus the 
findings of this work evolved from experiments that characterized the effects of low-dose 
infusions of HUCBC and HUCBC-derived monocytes into 6 month old Presenilin 1/Amyloid 
x 
 
Precursor Protein (PSAPP) plaque-developing transgenic AD mice.  Treated mice were studied 
using standard behavioral tests to determine the effects of infusion on the multiple cognitive 
domains affected by AD, followed by biochemical and histological analyses that included Aβ 
load and amyloid precursor protein (APP) processing.  Specifically, PSAPP mice and their wild-
type (WT) littermates were treated monthly with a peripheral HUCBC infusion over a period of 
6 and 10 months, followed by cognitive and motor evaluation.  Additionally, based on reports 
that tumor cells can originate from stem cells present in HUCB, we further examined whether 
monocytes purified from HUCBCs would have a similar significant effect on the reduction of 
AD-like pathology in PSAPP mice.  HUCB cells homed into tissues including the brain.  The 
principal finding was significant reduction in Aβ levels and β-amyloid plaques following low-
dose infusions of both HUCBC-derived mononuclear cells as well as HUCBC-derived 
monocytes, with the monocytes providing a stronger effect.  Results further demonstrated that 
HUCBC and HUCBC-derived monocyte infusion could improve memory function and 
locomotor ability in treated PSAPP mice.  A possible reason for behavioral improvements in 
these animals may be the significant reduction in both Aβ levels and plaque load.  This study 
also identified significant reduction in microglial activation and astrocytosis, both of which can 
contribute to AD pathology.  In conclusion, our data suggest that it might be the HUCBC-
derived monocytic population rather than stem cells that are responsible for the reduction in AD 
pathology. 
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CHAPTER ONE 
 
Introduction 
 
 
The impact of Alzheimer’s disease                                                                 
Alzheimer’s disease (AD), the most common age-related dementia (Ferri et al., 2005), is 
a neurodegenerative disorder clinically characterized by progressive cognitive impairments, 
memory deficits and modifications in personality.  While these basic characteristics of the 
disease still hold true today as they did back in 1906 when Dr. Alois Alzheimer first described 
the clinicopathological syndrome now known as AD (Selkoe et al., 2001; Hardy et al., 2002; 
Walsh et al 2005; Shankar et al 2008; Montine et al., 2012; Maurer 1997), there has been an 
unprecedented proliferation in numbers of those affected, hardly imagined by Dr. Alzheimer 
(McGeer et al., 2013).  This is due in part to increased longevity seen worldwide (Selkoe 2001). 
The Alzheimer's Association (2013 Alzheimer's disease Facts and Figures) report AD is the sixth 
leading cause of death in the United States.  Moreover, the greying of America’s “baby boomer” 
generation will undoubtedly result in a large increase in the number of AD patients.  This will 
result in a subsequent burden on the affected, their caretakers and society at large (Hebert et al., 
2013).  According to the World Alzheimer Report 2010 and Alzheimer’s disease International 
Statistics 2011, it is the most common form of dementia, affecting 35.6 million globally, and it is 
expected to increase to 65.7 million by 2030 and 115.4 million by 2050 if no effective treatments 
are discovered.  Currently AD accounts for around 1% of the world’s gross domestic product.  
The total estimated worldwide cost of dementia is US$604 billion (World Alzheimer Report 
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2010) and this is expected to soar based on predicted increases in the numbers of people who 
will develop dementia. Consequently, these escalating figures both in disease prevalence and 
treatment cost, should sound an alarm that rings out with an urgent plea for the need to 
understand the fundamental pathophysiology of AD, and to develop novel and effective 
therapeutic interventions.  
 
The pathology of Alzheimer’s disease                                                                 
 The earliest damage occurs in the entorhinal cortex, hippocampus and basal forebrain, 
structures in the brain that play a critical role in memory (Price et al., 2001).  Both postmortem 
and MRI studies on human brains have shown consistent findings that damage in these regions 
result in decreased brain volume (Convit et al., 2000, Chetelat et al., 2003, Bobinski et al., 1996, 
Juottonen et al., 1998) in AD patients as compared to age-matched controls.  As a result of the 
atrophy that occurs in both cortical and subcortical regions, patients suffer cognitive and 
emotional dysregulation eventually leading to an inability to perform activities of daily living 
(ADL) (Tanaka et al., 2013).  More specifically, while AD patient symptoms can be 
heterogeneous, the cardinal features of the disease includes a progressive diminished language 
function, slow global development of disordered cognitive functions,  progressive memory 
impairment, distorted  behavior inclusive of delusions, declined social appropriateness and 
paranoia (Iqbal et al., 2013, Selkoe 2001, Kivipelto et al 2005; Scarmeas et al 2009; Rusanen et 
al 2010).  Though the exact etiology of AD is elusive, clinicians and scientists have agreed that 
the principal risk factor that affects the likelihood of an individual developing the most common 
form of the disease (sporadic AD) is age (Hennebelle et al., 2013, Polyakova et al., 2013).  The 
incidence of the disease doubles every 5 years after 65 years of age, with the diagnosis of 1275 
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new cases per year per 100,000 persons older than 65 years of age (Hirtz et al., 2007).  Aside 
from age, other risk factors include family history of dementia, head trauma, genetic factors (e.g., 
apolipoprotein E [APOE] ε4 allele), female gender (Duara et al., 1993), low education level 
(Stern et al., 1994; Ngandu et al., 2007) , vascular disease (Kivipelto et al., 2005), and 
environmental factors (Rusanen et al., 2013; Scarmeas et al., 2009). 
It used to be that historically, the diagnosis of AD could only be definitively made 
following an autopsy and neuropathological examination of the brain.  Along with a clinical 
history of dementia, definitive diagnosis depends on the presence of characteristic AD hallmarks.  
These are an abundance of amyloid plaques in the brain neocortical parenchyma, which are 
primarily made up of deposits of the 4 kD  amyloid beta (Aβ) peptide and an abundance of 
intracellular neurofibrillary tangles (NFT), which are primarily composed of   
hyperphosphorylated  forms of the microtubule associated protein tau, that develop into paired 
helical filaments (Selkoe, 1996; Haroutunian et al., 20087; Mohaned et al., 2011; Serrano-Pozo 
et al., 2011; Kern and Behl, 2009; Mohajeri and Leuba, 2009).  What is more, apart from 
memory loss and the overarching pathological hallmark lesions, AD diagnosis also requires 
symptoms such as changes in mood or behavior and in personality (Lykou et al., 2013).  
Additionally, in some cases, there have been reports of ataxia and apraxia (Chainay et al., 2006; 
Derouesné et al., 2000; Della et al., 2004; Herbert et al., 2010), but not as major symptoms 
(Buchman et al., 2011; Anheim et al., 2007).  While this has been the standard for years, clinical 
intervention has been mainly confined to treating patients when pathology has reached an 
advanced stage.  On the contrary, technology has developed new diagnostic tools. Positron 
emission tomography (PET) using Pittsburgh compound (PIB-PET), as well as CSF levels of 
Aβ42, total tau (t-tau), phosphorylated tau (p-tau), p-tau/Aβ42, t-tau/ Aβ42 and plasma levels of 
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proteins such as α2-Macroglobulin, Complement factor H, Aβ42 can be used to predict AD 
pathophysiological processes in vivo, thus facilitating a more definitive diagnosis while patients 
are still living (Fraller et al., 2013). 
The classification of amyloid plaques in the human brain has evolved over the years to 
include subtypes of diffuse, primitive, neuritic, compact, cored, and cotton-wool (Mirra et al., 
1991; Braak et al., 1991; Castellani et al., 2010) plaques. Neuritic plaques are the most 
pathogenically relevant and are often highlighted as the plaque type of significance in the major 
consensus criteria for the diagnosis of AD at autopsy (Mirra et al., 1991; Castellani et al., 2010; 
Thal et al., 2013).  Brain regions affected early by plaques include the entorhinal cortex, 
hippocampus, and basal forebrain. Within recent times, Aβ deposition has been identified in the 
vascular wall; manifesting as cerebral amyloid angiopathy (CAA), a pathology frequently 
observed in as many as 83 percent of AD patients (Ellis et al., 1996). Tau tangle may be 
described as being “globose,” and “pre-tangles,” and are assigned significance based on location 
within the brain (Braak et al., 1991; Iqbal et al., 2008; Franko et al., 2013).  It has been 
postulated that the observed accumulation of Aβ in AD patients’ brains is due to its 
overproduction in the brain or the subsequent failure in its degradation and clearance from the 
brain milieu (Lemere et al., 2004; Zhu et al., 2013). Mutations in the APP and PS proteins 
(discussed in more detail later) are two known genetic causes that contribute to the familial, early 
onset form of AD (FAD) (Goate et al., 1991; Chartier-Harlin et al., 1991; McGeer et al., 2013;), 
while there are many genetic and environmental factors that may play a role, individually or in 
combination, in sporadic AD (SAD) (Piaceri et al,. 2013).  One well-known and critical outcome 
of  the APP and PS proteins mutations is a shift  in the two main forms of Aβ in the human brain, 
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namely from a production of Aβ that is 40 amino acids long (Aβ40) to toxic Aβ that is 42 amino 
acids long (Aβ42) (Haass et al 1993; Selkoe 2013).  
 
The structure and function of APP and Presenilin in AD 
        The main hypothesis for the cause of AD has been the “β-amyloid cascade hypothesis (Fig. 
1), which postulates that the chain of pathogenic events is initiated by an increased accumulation 
of Aβ40, 42 peptides (Hardy et al., 1992; McGeer et al., 2013).  The discovery of rare mutations in 
APP and PS proteins that result in significantly accelerated accumulation of Aβ proteins and 
earlier onset of disease (Goate et al., 1991; Zlokovic et al., 2000) has been widely used as 
support for the amyloid cascade hypothesis and for Aβ being the central pathological entity.   It 
is believed that the mutations in APP and PS increase Aβ peptide production,  Aβ  aggregates 
activate microglia and astrocytes.  These activations release cytokines and reactive oxygen 
species, disrupts synapse function, alters ionic homeostasis, enhances neuritic injury, alters 
kinase and phosphatase activities, and causes the formation of neurofibrillary tangles, and 
ultimately widespread neuronal dysfunction and cell death (McGeer et al., 2013; Hardy et al 
2002). 
        APP is a single-pass transmembrane (TM) domain glycoprotein.  The APP gene 
incorporates ~400 kb of DNA, contains 19 exons, and encodes several alternatively spliced APP 
mRNAs (Price et al 1998).  When the APP transcript is alternatively spliced it produces 8 
isoforms.  In the brain, the 695 amino acid isoform is expressed at higher levels while the 751 
and 770 amino acid forms are significantly expressed at lower levels. 
 
 
6 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Amyloid cascade hypothesis sequence of events (adapted from Reitz, 2012) 
 
             .  Although the  exact function of APP remains inconclusive, it has been reported to 
enhance cell health and growth in transgenic mice overexpressing wild-type APP and have been 
shown to modulate neurite outgrowth, motility, cell growth and cell survival in transiently 
transfected cell lines (Oh et al., 2009; Pearse et al. 1997). Secretase enzymes successively cleave 
the protein endoproteolytically.  APP mutations are normally located in the vicinity of cleavage 
sites.  When it is cut by α-secretases, APP processing results in a large soluble ectodomain 
fragment (sAPPα,), which is released into the extracellular domain, and an 83-amino acid 
carboxyl-terminal fragment (CTF), which is reserved in the membrane.  Alternative cleavage of 
APP by β-secretase results in a slightly smaller ectodomain derivative (sAPPβ) coupled with the 
retention of a 99-amino acid CTF in the membrane (Selkoe 1998).  The γ-secretase cleavage 
follows, and this generates the Aβ fragment that is released extracellularly (Fig. 2).  It has been 
reported that while 90% of secreted Aβ peptides are soluble Aβ40, only 10% of the secreted Aβ 
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peptide comprise the longer, more hydrophobic and toxic Aβ42.  Anatomically, Aβ42, a more 
fibrillar form, aggregates and deposits early on in the brain parenchyma in senile plaques (Price 
et al 1998) and can recruit Aβ into compact dense-cored plaques.  Aβ42, with little or no Aβ40 
immunoreactivity (Iwatsubo et al 1994), has been observed as the main component of diffused or 
‘cotton-wool’ plaques.  Conversely, Aβ40 accumulates in the vasculature and is the central feature 
of a disorder known as cerebral amyloid angiopathy (CAA). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 APP processing (adapted from Zheng et al., 2006) (simplistic model showing one 
cleavage site per each enzyme) 
 
Missense mutations in APP were characterized as the first specific genetic contribution to 
AD (Goate 2006; Chartier-Harlin et al., 1991).  These mutations are located within close 
proximity to the cleavage sites and result in early onset FAD (Brown et al., 1991) manifesting at 
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a relatively young inception age of 40 to 50 years old.  FAD accounts for less than 5 % of AD 
cases while conversely, SAD accounts for more than 95 % of AD cases (Hunter et al., 2013). 
Studies show that with the exception of the Swedish mutation, cells expressing various APP 
mutations do not appear to secrete higher Aβ levels rather they secrete a higher fraction of the 
more hydrophobic Aβ42 relative to cells expressing wild-type APP (Suzuki et al 1994).  The 
model in this study recapitulates FAD. 
        Presenilin 1 and Presenilin 2 (PS1 and PS2), components of γ-secretase that have been 
identified as the causative genes for autosomal-dominant familial Alzheimer's disease (FAD) 
(Borchelt et al., 1996; Scheuner et al., 1996; Tomita et al., 1997), have six to nine 
transmembrane domains.  Inherited missense mutations in PS1 or PS2 result in relative increases 
in Aβ42 production and cause AD in those <60 years of age (Selkoe 2013).  Most significantly, 
mutations in PS1 and PS2 have been reported to result in elevation of Aβ42 levels in human 
plasma, patient-derived fibroblasts and, in mice, showing strong toxicity (Borchelt et al., 1996; 
Scheuner et al., 1996).  There are over 50 mutations in the presenilin proteins that have been 
reported to cause FAD (Scheuner et al., 1996).  Such mutations result in an increased production 
of Aβ42 and less of Aβ40.  These proteins (PS1 and PS2) are highly homologous and are found in 
the intracellular membranes of the Golgi apparatus and the rough endoplasmic reticulum with 
their N- and C-terminal domains oriented toward the cytoplasm (Berezovska et al., 2005; Doan 
et al., 1996).  While the exact function of presenilin is not known, reports indicate that it plays a 
role in γ-secretase cleavage and intracellular protein trafficking.  Also, in the developmental 
signaling of Notch cleavage, presenilins are needed; the PS1 knockout mice displayed 
developmental abnormalities consistent with those observed in mice that had components of the 
Notch system knocked out (Wong et al 1997).  
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Although APP mutations are within proximity of the cleavage sites, presenilin mutations 
occur throughout the protein. Similarly to APP processing, when presenilins are processed and 
cleaved, they also produce an N- and C-terminal fragment (Borchelt et al., 1996); although it is 
not entirely well-defined as to whether it is the holoprotein or the protein fragments that 
constitute pathological or physiological significance.  While 30-50 %  of  FAD  is caused by 
mutations in the gene coding for the amyloid precursor protein (APP) or Presenilin-2 (PSEN2), 
mutations in the Presenilin-1 (PSEN1) gene are the most common causative factor of  this type 
of AD and accounts for  50-70% of cases (Ringman et al., 2008).  It has been observed that 
individuals with a single copy of a mutated PSEN1, APP, or PSEN2 gene experience a higher 
than 95% chance of developing AD at a relatively young age.  Moreover, their offspring has a 
50% probability of inheriting the mutated gene and consequently the disease trait (Ringman et 
al., 2008).  These and the other genetic findings mentioned above strongly support β-amyloid as 
the common initiating factor in AD in the amyloid cascade hypothesis (Hardy et al., 1992; 
Borchelt et al., 1996); the dominant hypothesis proposes that an increased accumulation of Aß42 
initiates the pathogenic torrent of events in AD.  Consequently, it is for these reasons we chose 
the FAD form as a valid model for uncovering critical clues and for testing effective therapeutic 
candidates for treating AD.  
 
Neuroinflammation, microglial morphology and stages of microglial activation 
 
Neuroinflammation 
 
In addition to the amyloid cascade hypothesis, studies investigating the amyloid cascade-
inflammatory hypothesis (McGeer et al., 2013) have also been explored.  Apart from AD being 
multigenic in complexity, as discussed above, Aβ deposition also results in an inflammatory 
10 
 
response mediated by cellular components such as microglia, the resident neuroimmune cells of 
the brain, and astrocytes (Mrak et al., 1996; Akiyama et al., 2000; McLarnon 2012).  This in turn 
activates signaling pathways that may potentially lead to neurodegeneration.  Immune system 
changes after brain injury have also been observed in cellular composition and functional 
modifications in the peripheral lymphoid organs, such the lymph nodes, spleen and thymus 
(Prass et al., 2003).  Spleens for example, in the stroke MCAO rat model  and the  Parkinson’s 
disease 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model, have been observed to 
undergo a reduction in both size and function (Benner et al., 2004; Gendron et al., 2002).  It is 
less clear as to whether the inflammation that is observed in the brains of AD patients is the 
actual cause of the disease or only a secondary event.  However, it has been proposed that 
micromolar concentrations of Aβ must be present in order to generate brain toxicity, and 
furthermore Aβ forms are present only at lower picomolar levels in the brain of healthy 
individuals throughout their lifetime (Seubert et al., 1992; Cittito et al., 2003).  Therefore, it is 
highly unlikely that Aβ in itself could be the cause of AD.  This model speculates that AD results 
from a triad, involving inflammation generated in reply to Aβ deposits and that has been boosted 
by tau aggregates (Akiyama et al., 2000).  How tau aggregation is set in motion by amyloid 
deposition still eludes scientists and clinicians, but it is fully accepted that inflammation is 
induced by extracellular amyloid deposits (Akiyama et al., 2000; Kitazawa et al. 2004; Meraz-
Ríos et al, 2013).  Briefly, from that idea, it appears that increased APP levels or amyloidogenic 
processing leads to increased Aβ which consequently leads to increased inflammation via 
microglial activation around plaques and throughout the brain; and these events are 
interdependent (Akiyama et al 1996).  
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Microglia morphology 
During the early stages of embryonic development, monocyte derived cells enter the CNS 
and develop into microglia (Murabe et al., 2005).  Once developed and resident in the brain 
parenchyma, microglia in a resting stage typically have a highly ramified phenotype that 
eventually forms a uniform reticular array in both gray and white matter.  These macrophage-
related cells are the prime immune effector cells of the CNS (Hanisch et al., 2007).  Although 
microglia serves to support and sustain proper neuronal functioning, several studies attest to 
microglia’s critical role in the etiology of various neurodegenerative diseases (for review see 
Kaushik and Basu, 2013).  
When certain pathophysiological conditions exist, microglia can remain in an activated 
state for an extended time, during which they secrete various inflammatory factors.  This 
chronically activated state is thought to cause and preserve an inflammatory response that may 
result in the neuronal cell loss observed in disease conditions such as AD (El Khoury et al., 
2008), Parkinson’s disease (Song et al., 2013; Orr et al., 2002), HIV-dementia (Yadav et al., 
2009; Tcherakian et al., 2013), multiple sclerosis (Raivich et al., 2004; Kishore et al., 2013), and 
amyotrophic lateral sclerosis (Lee et al., 2013; Sargsyan et al., 2005).  Moreover, this prolonged 
activation can expose the CNS to levels of a wide array of potentially neurotoxic molecular 
mediators including acute-phase pro-inflammatory chemokines and cytokines like IL-1β, IL-6, 
IL-10, TNF-α, and TGF-β (Blum-Degen et al.,1995; Tarkowski et al.,2002; Mrak et al, 2005; 
Jiang et al., 2011), proteases, complement proteins (which use the C1q molecule), mannose-
binding protein or C3 multifunctional protein interaction, to recognize molecular patterns on 
pathogens (Meraz-Ríos et al., 2013), nitric oxide (NO) and reactive oxygen species (ROS) 
(Akiyama et al., 2000; Kitazawa et al., 2004).  Additionally it has been established that Aβ and 
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its N-terminal fragments bind to C1q and thus directly activate the complement system and 
initiates the AD inflammatory cascade (Rogers et al., 1992).  Further impacting the inflammatory 
milieu, microglia are capable for expressing Fc receptors, receptors for advanced glycosylation 
end products, Prostaglandin F receptors (FP) receptors, various scavenger receptors and CD40 
(Okun et al., 2010; El Khoury et al., 1998; Tan et al., 1999; Walker et al., 2005).  On the other 
hand, there is an alternative theory that postulates that dysregulation of microglial activation can 
inhibit the appropriate immune responses necessary to respond to neuroinsults (Morgan et al., 
2005).  As such these inflammatory cellular and molecular mediators have been associated with 
a sequence of concomitant deleterious and beneficial outcomes. 
Microglia classification in brain tissue has traditionally been done based on their 
morphology. Change in shape has been implied to reflect change in function.  Microglia rapidly 
changes its phenotype in response to any disturbance of nervous system homeostasis.  Branched 
microglia are highly dynamic and use their long cellular extensions to scan the brain (Kreutzberg 
et al., 1996; Davalos et al., 2005; Nimmerjahn et al., 2005).  In brain parenchyma, there is an 
abundance of ramified microglia (Colton et al., 2010).  In adults, this phenotype represents 10-20 
% of the total population of glial cells (Colton et al, 2010).  These small round cell bodies (soma) 
comprise numerous branching processes and possess little cytoplasm.  While the full repertoire 
of ramified microglia is not known, they appear to be long-lived cells with a limited potential to 
divide.  Microglia can also respond very quickly to subtle changes not associated with any 
apparent tissue damage (Fig. 3), such as spreading electrical depression (Gehrmannet al., 1993; 
Hanisch et al., 2007) as well as more severe insults such as anoxic-ischemic injury and neuronal 
loss associated with a host of degenerative disorders with a sequence of antigenic and 
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morphological changes.  The latter intermediary form is less ramified, with more abundant 
cytoplasm.  
Primed microglia phenotypes exist in the aging brain.  This facilitates an altered cytokine 
profile when compared to young brains (Perry et al., 1993; Sierra et al., 2007).  Primed microglia 
produce exaggerated inflammatory responses when activated (Perry et al., 2007; Godbout et al., 
2005).  It is this increased inflammatory status of microglia within the aging brain that is referred 
to as primed or sensitized.  This condition leads to prolonged proliferation cycles and production 
of pro-inflammatory cytokines and eventually, neurotoxicity. Importantly, recent reports showed 
that microglia from aged environments are not skewed towards the alternative (M2) response 
(Lee et al., 2013) (see section 1.3.3 for microglia activation states). Briefly, the hippocampus of 
6, 12, or 24 month old mice was injected with a cytokine cocktail containing either tumor 
necrosis factor (TNF)-α, interleukin (IL)-12, and IL-1β (referred to as CKT-1) or IL-13 and IL-4 
(referred to CKT-2), and tissue subjected to microarray analysis 3 days later.  It is widely known 
that the cytokines in CKT-1 cocktail are associated with the pro-inflammatory response, 
representing the M1 classical microglia activation state while the cytokines in the CKT-2 are 
associated with the anti-inflammatory response, representing the M2 alternative activation state. 
In the study, gene transcripts from both CKT-1 and CKT-2 stimulator cocktails were evaluated.  
The results revealed that while CKT-1 induced selective transcripts at all ages, CKT-2 induced 
selective gene transcripts decreased with age signifying that there was a reduction in the IL-4/ 
IL-13 signaling pathway in an age-related manner (Lee et al 2013). 
 Ramified or resting microglia constantly receive tonic inhibitory signals from nearby neurons.  
When this cross talk (Nelson et al., 2002) and other endogenous signal fail,   as in cases of  
injury or pathogen invasion, quiescent ramified microglia proliferate and transform into active 
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‘brain macrophages’ otherwise known as reactive microglia (Garden et al., 2006) and migrate to 
injury sites.  The soma increases in this microglia and branching decreases.  Significantly, in this 
state, microglia acquire an amoeboid form and express various specified cell surface markers 
(Town et al., 2005).  It is this population of macrophages which are associated with brain injury 
and neuroinflammation.  After damage occurs, reactive microglia accumulate at the site of injury 
(Banati et al., 1996; Hanisch et al., 2007; Lobsiger et al., 2007; Streit et al., 2002).  Activated 
microglia association around neuritic plaques in AD suggests that they contribute to the Aβ 
accumulation reported in patients with AD and Downs syndrome (Glenner et al., 1984).  This 
notion was further supported by several studies (Rozemuller e al., 1986; Dickson et al., 1988).  
In response to the cytokine milieu, these microglia express a vast repertoire of receptors and in 
turn, phagocytize damaged cells and debris, that is, they act as neuroprotective agents.  
 
Microglial Activation 
Historically, in terms of functional groups, microglia, like macrophages, can be 
categorized as being ‘classically activated’ or M1, which generates elevated levels of pro-
inflammatory cytokines, chemokines NOS and ROS, and ultimately result in tissue injury, or 
‘alternatively activated’ or M2, which is considered to be anti-inflammatory, repressing toxic 
immune reactions and promoting tissue remodeling (Gordon et al., 2010; Miron et al., 2013).  
Neurotoxic M1 microglia and neurotrophic M2 microglia can co-exist in the inflammatory 
environment in a delicate flux. This was demonstrated in primary cultured hippocampal 
microglia from the transgenic PS1M146L/APP751SL mouse model of AD and in addition from 
a murine microglial cell line (Jimenez et al., 2008).   
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Fig. 3 Microglial activity states (adapted from Hanisch et al., 2007) 
. 
What is more, that study demonstrated that the transgenic PS1M146L/APP751SL mouse model 
of AD showed an age-dependent shift from initially being in an alternative M2 state to a being in 
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a classical M1 activation state.  This occurrence may be plausible in other neurodegenerative 
diseases as was observed in functional tests of microglia from CNS injured normal mice (Kigerl 
et al., 2009). These mice displayed brief transient anti-inflammatory M2 response that was 
rapidly surpassed by the M1 neurotoxic response.  
Consequently a range of early pathological studies have shown that activated microglia 
and reactive astrocytes are clustered around plaques and tangles (McGeer et al., 2013; Kaushik et 
al., 2013), suggesting that these structures may be activating these cells to an inflammatory state.  
The consequences of microglia activation have been well documented with the production of 
damaging cytokines (Meraz-Rios et al., 2013).  While it was once thought that activation of 
microglia and astrocytes in the AD brain were an epiphenomenon and not a pathoetiological 
contributor to AD, more recent studies implicate the Aβ-mediated inflammatory cascade as an 
etiological perpetrator of AD (Biscaro et al., 2012).  For example, therapeutic strategies aimed at 
manipulating this inflammatory cascade, including Aβ immunization, non-steroidal anti-
inflammatory drugs (NSAIDs), and modulation of microglial activation, are all able to reduce 
AD-like pathology and improve neurocognitive impairment in AD transgenic mouse models 
(Biscaro et al., 2012).  
Extending on the observation that microglia express a vast gamut of receptors when an 
inflammatory response is mounted, recently we reported that the CD40–CD40 ligand (CD40L) 
interaction plays a crucial role in Aβ-induced proinflammatory microglial activation (Tan et al., 
1999). Further, we showed that when this signaling pathway was disrupted, cerebral Aβ deposits 
in the Tg2576 AD transgenic mouse model was reduced and cognitive deficits improved in 
PSAPP AD mice (Tan et al., 2002; Todd et al 2004; Town et al., 2001; Tan et al., 2002). Studies 
such as those reporting increased expression of CD40 and CD40L in and around β-amyloid 
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plaques in AD brain (Calingasan et al., 2002; Togo et al., 2000) strongly support the suggestion 
of the CD40–CD40L interaction in AD-associated brain inflammatory process.  
Studies with MS patients revealed that not only were activated Th cells expressing the 
CD40 ligand (CD40L) detected in MS patients’ brains, moreover these cells were intimately 
juxtaposed to CD40-bearing cells in active demyelinating lesions (Gerritse et al.,1996).  This and 
other studies opened the way for the now broadly accepted tenet that CD40 is expressed on many 
professional and nonprofessional APCs, including dendritic cells, B cells, 
monocytes/macrophages and microglial cells (Tan et al., 1999b; Carson et al., 1998; O'Keefe et 
al., 2002; Havenith et al., 1998; Tan et al., 1999a) and exists as a heteromultimeric complex on 
the cell surface (Tan et al., 2002a).   CD40 is a type I transmembrane protein which when mature 
is comprised of 277 amino acids with a 193-amino-acid extracellular domain, including a 21-
amino-acid leader sequence, a 22-amino-acid transmembrane domain and a 62-amino-acid 
intracellular tail.  CD40L, the associated CD40R ligand, is a significant immunoregulatory 
molecule that exhibits a co-stimulatory role in the activation of immune cells from both the 
innate and adaptive arms of the immune system.  This function encompasses activation, 
maturation/differentiation, growth/proliferation, and regulation of apoptosis.  Although CD40L 
may sometimes be secreted as a small soluble factor, normally it is expressed by activated CD4+ 
and certain CD8+ T cell subsets (Grewal et al., 1998). 
It has been reported that the ligation of CD40 generates APC activation and subsequently 
activation of cytotoxic T lymphocyte function in CD8+ T cells and this can result in a halt of 
viral infection and tumors (Clarke, 2000).  In addition, interaction of the CD40-CD40L also 
regulates the humoral or antibody arm of the immune response.  More specifically, CD40L on 
the surface of activated T cells interacts with B cell CD40 producing an accessory signal that 
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stimulates B-cell proliferation and differentiation into antibody-secreting plasma cells, initiates 
the IgM to IgG antibody isotype switch, and opposes B-cell apoptosis (Jelinek, 2000; Kishimoto 
et al., 2000).  As observed, there is a Th cell immune deviation from a Th2 to a Th1 immunotype 
(Martin et al., 2010), resulting in an optimized cellular immune response necessary for 
counteracting primary infection.  Indeed earlier experiments from this and other studies have 
shown that both microglia and astrocytes constitutively express CD40 at low levels (Tan et al., 
1999b; Aloisi et al., 1999). When microglia were stimulated with between 1 and 10 U/ml of IFN-
γ and  TNF-α, microglia dose-dependently increased expression levels by as much as 20-fold 
with IFN-γ and  by a lesser degree with TNF-α (Tan et al., 1999b, Nguyen et al., 2000; Aloisi et 
al., 2000).  This observation whereby the CD40-CD40L interaction leads to a striking production 
of tumor necrosis factor-α (TNF-α), a cytokine that has been found to mediate neuronal injury in 
vitro (Tan et al., 1999b), supports the idea microglial CD40 may significantly affect 
neuroinflammatory pathogenesis. Moreover, in elucidation efforts, studies have sought to 
directly inhibit the interaction using a neutralizing antibody to CD40L.  The experimental 
allergic encephalitis (EAE) mouse model of MS was used to examine a possible mode of action 
for blocking the CD40-CD40L interaction by interrupting Th1 cell differentiation and function 
(Howard et al., 2003).  While peripheral Th1/Th2 mechanisms’ importance in other disorders is 
well known, their role in AD and other neuroinflammatory disorders is currently being explored. 
In AD, preliminary experiments of the study presented in this dissertation (Nikolic et al., 
2008) reported a noticeable reduction (p < 0.001) of Aβ levels/β-amyloid plaques and associated 
astrocytosis in the PSAPP AD mouse model when treated with multiple low dose infusions of 1 
x 10
5
 human umbilical cord blood cells (HUCBCs), bi-weekly for the first two months and 
monthly for the remaining four months.  It was found that these infusions also reduced cerebral 
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vascular Aβ deposits in the Tg2576 AD mouse model. Such findings were associated with 
suppression of the CD40-CD40L interaction as evidenced by elevated systemic IgM levels (p < 
0.05), attenuated CD40L-induced inflammatory response, diminished circulating and brain 
soluble CD40L (sCD40L) and reduced microglial CD40 surface expression. Additionally, 
microglia isolated from HUCBC-infused PSAPP mice exhibited an augmented Aβ phagocytosis. 
HUCBC-infused PSAPP mice sera displayed considerably improved microglial phagocytosis of 
Aβ1-42 peptide while inhibiting IFN-γ (100 ng/mL) -induced microglial CD40 expression.  
Consequently, these experiments suggest that HUCBC infusion disrupts CD40L activity thus 
modulating AD-like pathology. While this finding increased our repertoire of therapeutic 
possibilities for AD, it was not known if this observed reduction in pathology correlated to 
rescue of behavioral (learning and memory) deficits. Thus, apart from reducing AD pathology 
the focus of the proposed study was largely to investigate whether HUCBCs could improve 
cognitive function in the PSAPP transgenic mice model of AD. 
There is no true disease modifying treatment for AD.  The U.S. Food and Drug 
Administration have approved 5 drugs that improve AD symptoms only temporarily (Di Santo et 
al., 2013).  One of the drugs, Aricept (donepezil), a reversible inhibitor of acetylcholinesterase, 
has been approved for mild to moderate stages of AD, and is temporarily effective in improving 
cognition.  This would be expected since acetylcholine is linked to learning and memory.  It is 
becoming increasingly evident, however, that intervention is urgent and a more effective 
treatment or prophylaxis is needed. 
Current experimental therapies have focused on removal of Aβ or prevention of its 
accumulation.  Current theories suggest that prevention of accumulation of toxic Aβ levels will 
prevent much of the direct neurotoxic effects along with prevention of its activation of the brain 
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immune system (Zhu et al., 2013).  Aβ plaques are potent activators of both microglia and 
astrocytes-central nervous system (CNS)-resident immunocompetent cells that respond to 
cerebral amyloidosis by chronic, pro-inflammatory activation, also known as “inflammaging” 
(McGeer et al., 2013; Klegeris et al., 1994; Giunta et al., 2008).   
 
Animal model of amyloid deposition and other models of AD-like pathology 
 While the two major hallmarks of AD are A plaques and hyperphosphorylated tau 
tangles, the existence of neuron loss has also been reported, together with gliosis, depression, 
anxiety and other psychological symptoms (Gómez-Isla et al,. 1997; Jung-Eun et at., 2013; 
Serrano-Pozo et al., 2011; Selkoe 2001).  However, amyloid appears to be the major culprit 
contributing to AD (Morgan 2000).  Cognitive decline is a key facet of AD and parallels between 
memory dysfunction and age-dependent increases in the core densities of amyloid plaques 
suggest that amyloid plays a critical role in this decline (Janus et al., 2001; Kelly et al., 2003).  
Consequently, this study of this dissertation sought to develop therapies that decreased amyloid 
burden and reverse memory impairments.  Mouse models of AD must be closely linked to 
hallmarks of the disease (Castellani et al., 2006).  While the exact pathological significance of 
Aβ and NFT individually and collectively are not known (Arriagada et al., 1992; Roberson et al., 
2007), many AD models are deemed valid based on either their ability to overexpress APP 
mutations that cause plaques and/or phosphorylated tau mutations that cause tangles in the brain.  
However, authentic modeling of all AD features in such mice remains obscure (Cohen et al., 
2013).  
While different animal models have mimicked various AD hallmarks in isolation, it was 
only in recent years that animal models have been able to recapitulate a combination of these 
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pathologies whose presence is required for diagnosis of AD (Table 2 below).  In terms of animal 
models of amyloid deposition, of critical importance are extracellular amyloid deposits in the 
brain parenchyma as plaques and in conjunction with the blood vessels as cerebral amyloid 
angiopathy (CAA). In terms of animal models of tau intracellular inclusions, NFTs are present in 
the brain where the neuron died, thus disrupting cellular signaling and communication.  
Presently, various models exist, including amyloid precursor protein (APP), tau, APP+PS and 
even triple transgenic models. 
PDAPP, Tg2576, TgCRND8, hAPP/hACT and PSAPP are some representative amyloid 
precursor protein (APP) AD models.  APP mutations around the -secretase or -secretase 
cleavage sites increase secretion of Aβ42 in the brain (Jang et al., 2013).  In these transgenic 
mouse models that use mutated APP, the inserted genes are  controlled by different promoters, 
including the prion protein (PrP) (Hsiao et al., 1996), thymocyte differentiation antigen 1 (Thy-) 
(Sturchler-Pierrat et al., 1997) and the platelet-derived growth factor β-chain (PDGFβ) (Games et 
al., 1995).  PDAPP, the first model to depict overexpression of -amyloid was driven by the 
PDGFβ promoter.  This model expresses a human APP variant 695/751/770 minigene encoding 
the V717F mutation (the London mutation) (Games et al., 1995).  At around age 6 months, this 
model exhibits an onset of amyloid deposition and increase in APP mRNA expression levels in 
the brain while at 13 months, they begin to show behavioral deficits (Chen et al., 2000).  The 
Tg2576 model is hamster PrP-driven. Tg2576 expresses hAPP695 and contains the double 
mutation, K670N/M671NL (Swedish mutation) (Hsiao et al 1996) resulting in amyloid 
deposition and cognitive decline starting around 6 months old (Hsiao et al 1996; Westerman et 
al., 2002).  TgCRND8 (Chishti et al., 2001), like the Tg2576 model, is also hamster PrP-driven.  
Likewise, it also expresses hAPP695 but contains an additional mutation, (V717F) conferring γ-
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secretase cleavage which yields, by 3 months of age, both decline in cognition and amyloid 
deposition (Chishti et al., 2001).  The hAPP/hACT doubly transgenic mice, a cross between 
hAPP mice that produce human amyloid protein precursors (hAPP) and Aβ in neurons (Johnson 
et al., 1995) and human α1-antichymotrypsin (hACT) transgenic mice, has an onset of florid 
amyloid plaques at age 7 months and show progressive decrease in synaptophysin-
immunoreactive presynaptic terminals in the dentate gyrus (Mucke et al., 2000). PSAPP (double 
transgenic model: TgAPPswe/PS1dE9), like the Tg2576 model, is cut at the β-secretase cleavage 
site and has the K670N/M671L Swedish mutations and PS1 (PS1dE9).  PSAPP is a model of 
amyloid deposition and lacks the development of NFTs or neuronal loss.  It is mouse PrP-driven 
and incipient deposition starts at 3 months old (Wang et al., 2012, Holcomb et al., 1998, 
Holcomb et al., 1999) with appreciable amyloid deposition and memory dysfunction at 6 months 
old (Kim et al., 2012).  
Other models have also sought different angles to recapitulate and subsequently treat AD.  
Hyperphosphorylated tau models, such as the JNPL3 model, produce tau-associated pathology 
but lack the development of amyloid plaques. The tau JNPL3 model is mouse PrP promoter-
driven and expresses human tau with the P301L mutation, the most common mutation found in 
fronto temporal dementia, not AD.  In this model, around 5 months of age, and specifically, in 
the hemizygous animals, NFTs and progressive motor deficits develop (Lewis et al., 2000).  The 
triple transgenic model of the APP+PS+TAU mice (3XTg) represents yet another AD model. 
This transgene is mouse Thy-1 promoter-driven and expresses human APP695 (Swe), PS1 
(M146V), and Tau (P301L).  While synaptic dysfunction is observed before plaque and tangle 
pathology (Oddo et al., 2003), cognitive dysfunction correlates with intraneuronal amyloid 
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deposition at around 3 month old, (Billings et al., 2005).  Robust dense cored plaques develop at 
6 months of age and NFTs at around 12 months of age (Oddo et al., 2003). 
 
Table 2 Commonly used AD mouse models 
Model  Mutation Phenotype Cog. Symptom of 
Neuro-degeneration Onset 
(mths) 
Plaque NFT Neuron 
Loss 
CAA 
PDAPP 
[Huitron-Resendiz et 
al., 2002, Games et 
al., 1995] 
Human 
APP 
6 ++ +/- - + ++ 
Tg2576 
[King et al., 2002, 
Hsiao et al., 1996] 
Human 
APP 
6 ++ +/- - + ++ 
TgCRND8 
[Faizi et al., 2012, 
Chishti et al., 2001] 
Human 
APP 
2-3 +++ +/- - ++ ++ 
APP23 
[Sturchler-Pierrat et 
al., 1997] 
Human 
APP 
6 ++ +/- - ++ ++ 
PSAPP 
[Wang et al., 2012, 
Holcomb et al., 1998, 
Holcomb et al., 1999] 
Human 
APP. 
Human 
PS1 
3 ++++ +/- - + ++++ 
JNPL3 
[Lewis et al., 2000] 
Human  
Tau 
4.5 - +++ + - +/- 
rTg4510 
[Santacruz et al., 
2005] 
Human 
Tau 
3 - +++ ++ - +++ 
3XTg 
[Oddo et al., 2003] 
Human 
Tau. 
Human 
APP. 
Human 
PS1 
3 ++ +++ - +/- ++ 
APPSw/ NOS2 -/- 
[Colton et al, 2006] 
Human 
APP. 
NOS 
deletion 
 
6 +++ ++ +++ ++ +++ 
APPSwDI 
/NOS2 -/- 
[Wilcock et al., 2008] 
Human 
APP. 
NOS 
deletion 
3 ++++ ++ +++ +++ +++ 
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Currently, no individual AD model is perfect in that no one model accurately reflects all 
the hallmark pathology, memory dysfunction, behavior changes, and construct validity.  In trying 
to harness and reproduce the disease effects, PSAPP mice was the best model for the study 
because it most closely mimicked the robust amyloid deposition associated progressive decline 
seen at the various stages of AD, from mild to severe (Morgan et al., 2000; Wang et al., 2012).  
Age-dependent pattern of plaque deposition and anatomical distribution of A variants (both 
long and short) in this model begins at around 3 months and realistically reflects the human 
disease (Wang et al., 2012; Morgan et al., 2000) and by age 14 months this model develops the 
florid cognitive decline reflective of moderate to severe AD (Morgan et al., 2000).  
Consequently, we believe that the PSAPP model is the model of choice for this AD study due to 
its ability to recapitulate key features of pathology, memory dysfunction and behavioral changes. 
 
 
Behavioral paradigms 
 A progressive cognitive decline due to hippocampal neuron and synaptic loss is the most 
predominant and striking sign in AD patients.  The PSAPP AD-like model accurately 
recapitulates in mice the corresponding memory changes observed in human AD patients.    For 
the purpose of this and other studies, behavioral tests were categorized as either associative 
(conditioning a specific response from the model using environmental cues) or operant 
(obtaining a consequence by allowing the model to make a specific response to a particular 
stimulus) learning tasks. These cognitive tasks were further sub-divided into groups reflecting 
the evaluation of the particular type of memory. 
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Spatial memory  
           The Radial Arm Maze (RAM) is able to evaluate working and reference memories 
simultaneously.  Test animals use spatial cues to guide them to food or water rewards located in 
various arms of this maze. The aim is to have the animal use the shortest time possible to enter 
each arm in the maze once to get the most reward. As such, RAM uses the model’s working 
memory to remember information that is required within the short trial moment. More 
specifically, during the trial periods, cohorts must not only refrain from entering arms of the 
maze that are not baited (reference memory), but they must also recall the arms that are baited as 
well as those arms they had previously entered (working memory) earlier in the trials. Recalling 
the overall rules during the entire length of the test also utilizes reference memory.  Drawbacks 
in RAM include odor misperceptions and the animal models are deprived of water and food 
(Morgan et al., 2000).  This test evaluates distance travelled and latency to reach goal. 
 The Morris Water Maze (MWM) is highly specific measurement of hippocampal 
function and is one of the predominant tests used to measure hippocampal spatial memory 
deficits (Brandeis et al., 1989).  While it is sensitive to AD-like, age-related discrepancies, and 
therefore an appropriate task, it is limited in that it is unable to test working and reference 
memories, simultaneously. Motivation here, involves water escape.  This test evaluates distance 
swam, latency to reach the platform, and swim speed.   
 Radial Arm Water Maze (RAWM) combines the benefits of the design flexibility of the 
dry RAM and the motivational advantages of the MWM.  This test is very similar to MWM but 
it is more difficult in that it requires that the animal locate a goal (platform) that is submerged.  
Time elapsed prior to finding the platform (latency to escape) is recorded.  The animal is 
compelled to use spatial cues and working memory (Morgan et al., 2000, Gordon et al., 2001) to 
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recall goal location.  The reference memory variant of the RAWM reveals deficits in memory 
performance (discussed more in chapter 2).   
 
Contextual memory 
 In the Passive-Avoidance cognitive test, the animal is required to learn to avoid darkness 
(considered a mild aversive stimulus).  Gravitating to darkness is an innate response in rodents. 
Animals that remember the aversive foot-shock stimulus take longer to cross over into a 
darkened chamber than animals that do not remember.  Passive-Avoidance evaluates latency to 
cross into the unsafe chamber and the percentage of each group of experimental animals to cross 
the threshold within an assigned time dependently cross the threshold measures (Lawlor et al., 
2007; Senechal et al., 2008).  
         In Fear Conditioning, the cue dependent measurement is the mean percent freezing 
response.  Rodent’s innate response to fear is to freeze.  Here pairing of conditioned (tone) and 
unconditioned stimuli (shock) results in freezing upon hearing the tone.  This test is sensitive to 
emotion-associated learning and measures amygdalar - hippocampal (fear and anxiety) 
communication and hippocampal-dependent associative learning which may differ from spatial 
task learning (Fanselow et al., 1980, 1988; Hamann et al., 2002).   
 
Working memory/novelty/activity 
 Object-Recognition cognition tasks are sensitive to age-related deficits (Shukitt-Hale et 
al., 2001; Casadesus et al., 2004; Janus et al., 2000) and evaluate spatial recognition and novelty 
by utilizing variously configured environments and objects.  Mice have an innate preference to 
investigate novel objects instead of familiar ones.  When the new environment is removed, they 
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also have a natural tendency to restart exploration.  Sidedness, preference and simple learning 
can all be addressed by this task. After completion of the various trials, the number and length of 
time objects are explored and movement or inactivity during the time spent exploring are 
measured (Sik 2003).          
The Y-Maze capitalizes on this innate preference.  When exploring novel environments, 
mice prefer to alter their entrance location.  The animal is required to remember and not reenter 
the arm last entered, and as such, a high alternation rate is indicative of sustained cognition 
(Drew et al., 1980).  Y-Maze tests both short and long term memory and includes evaluations 
such as first arm entered, time spent in arm, arm entries total and learning curves. 
 The T-Maze cognitive behavioral test is sensitive to hippocampal dysfunction.  Animal 
are allowed to enter the maze either spontaneously (alternating arm entry by remembering its 
first choice) (Decon et al., 2006; Shoji et al., 2012) or by reward and these observations may be 
strengthened by rewarding the animal with its food preference when it is hungry.  Avoidance 
latencies can be analyzed. 
The Open Field locomotion task evaluates activity in an open field and gives an 
indication of motor function.  Behavior and anxiety is calculated by making observation on 
general movement, line crosses, number of lines crossed, preference for particular sections and 
fecal movements (Hrnkova et al., 2007).   
 
Swim test 
 The Open Pool Swim Test is usually conducted during the last day of the test battery to 
examine whether the animals possess the skills sufficient to complete the water maze task 
(Alamed et al., 2006).  Here, just as in the RAWM test, each mouse is tested and latency to reach 
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the platform is recorded.  Mice are considered as having a possible swimming or visual deficit if 
they do not accomplished reaching the platform within the 20-second latency criterion for the 
last 3 trials of the visible platform task and are thus excluded. 
 
Rotarod locomotor test  
  This test assesses how well rodents maintain balance and keeps pace with a rotating rod, 
and is a good measure to assess motor function. This test is more widely used in assessment of 
movement disorders where substantia nigra or PD like disease is being modeled, however it was 
included in this study’s test battery following reports that in some cases of AD, there have been 
reports of ataxia and apraxia (Chainay et al., 2006; Derouesné et al., 2000; Della et al., 2004; 
Herbert et al., 2010) additionally it added a motor component to the cognitive testing.  The main 
objectives of this sensorimotor task are to exclude the possibility that positive effects of any 
treatment in the cognitive tasks are due to differences in sensorimotor ability.  Mice are placed 
on a rod and the rod is allowed to steadily accelerate up to 40.0 rpm over a 3-minute session. 
Evaluation is made by monitoring clinging from the top of the rotating barrel or by latency to 
fall.  In brief, the latency of the mouse to fall from the drum was the measure of motor 
coordination. Improvement across trials was the measure of motor learning.  
 
 In summary, while the cognitive tasks measure various aspects of memory, the RAWM 
was this study’s test of choice because it encompasses the better of two well-known tests without 
adverse treatment of the animal.  These benefits necessitate no motivational elements such as 
food deprivation or foot shock (Alamed et al., 2006).  The RAWM presents both the intricacies 
of the use of spatial cues and the ease of measurement of the dry radial arm maze pooled together 
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with the merits of the Morris water maze robust motivation and brisk learning.  It tests both 
working (short term) and reference (long term) memory and thus it is a significant indicator as to 
the effect of therapeutic intervention in AD. Additionally, directed by recent reports of ataxia and 
apraxia, though not as major symptoms, in AD, we investigated this motor component by using 
the rotarod test that assessed not only how well the mice learned to balance on the rotating rod. 
We also use the open pool visual acuity swim test to evaluate whether the cohorts has the 
necessary skill set to complete the RAWM.  
 
Stem cells  
 Cell therapy has demonstrated promise as a viable treatment for this devastating disorder 
(Nikolic et al., 2008). As briefly mentioned, modulation of immune/inflammatory responses 
reduces neurodegeneration.  Transplantation of stem cells, as a  putative treatment of 
neurological diseases in human,  has evolved as  a viable  method within recent times (Kim et al., 
2009; Park et al. 2009).   
Stem cells are self-maintaining and able to self-renew and proliferate during the 
organism’s lifetime.  These cells are hierarchal and may produce cells that are further 
differentiated (Blau et al 2001; Marshak et al 2001).  Stem Cells can be classified as Ancestral 
Stem Cells - generate offspring that can be further differentiated.  Pluripotent Stem Cells - after 
development of the blastula, these cells develop from the inner cell mass and can differentiate 
into germinal and somatic tissues. These stem cells yield cells occupying the three embryonic 
germ layers, mesoderm, endoderm and ectoderm.  Multipotent, Bipotent and Unipotent Stem 
Cells - Stem cells that are further differentiated, restricted, daughter cells of pluripotent or 
totipotent stem cells (Blau et al 2001; Marshak et al 2001).  Cells from hematopoietic origin 
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constitute one of the most promising sources for human stem cells. Such cells are found in 
HUCB (Mayani et al., 1998), adult peripheral blood, and bone marrow.  While stem cells have 
therapeutic value, not all yield the same level of benefits (Table 2).  
 
Table 2.    Key advantages of HUCBC stem cells compared to other stem cells as 
therapeutic agents (adapted from Harris 2009) 
 
 
 
 
HUCBCs as a potential therapy for neurological diseases 
 
 The therapeutic potential of HUCBC stem cells in nervous system disorders has been 
documented in a wide number of studies using animal models of neurological diseases including 
those of AD (Ende et al., 2001) and stroke models (Chen et al., 2001).  HUCBCs, harvested from 
the umbilical cord of newborn babies, have unique immunomodulatory/alteration potential.  
Unlike cells from the bone marrow, these cells are easily obtainable and very easily 
Stem Cell Types Advantages  Limitations 
Embryonic stem cells  
 
High development potential 
High proliferative capacity 
Little risk of viral contamination 
 
Limited supply 
Ethical issues 
No clinical data 
Biological constraints 
Newborn stem cells: 
HUCBC 
 
Younger, excellent proliferation 
and differentiation abilities 
Immediately available 
Less stringent HLA requirements 
Lower risk of GVHD, infections 
Autologous transplants possible 
 
Delayed short-term engraftment 
One-time supply 
 
Adult stem cells: 
Bone marrow 
Ability to differentiate 
Rich concentration of stem cells 
Greater amount of historical data 
Rapid engraftment 
 
 
Complex harvest 
Minimal residual disease (MRD) 
Increased potential for GVHD 
 Peripheral blood Good historical data  
Less invasive than bone marrow 
Facilitates easier autologous 
transplants 
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cryopreserved for future use (Goodwin et al., 2003).  HUCBCs are immune immature cells and 
thus facilitate a low occurrence of graft versus host disease (GvHD) following cell 
transplantation compared to other cell based therapies (Rocha et al 2001; Lewis et al. 2002; 
Gluckman et al., 2001).  Clinically they are safe and have been used for over ten years in the 
management of myeloablative and nonmyeloablative blood diseases, while more recently, 
HUCBC therapy has been used in neurodegenerative diseases and injuries (Lu et al., 2002;  
Garbuzova-Davis et al., 2003; Zhao et al., 2004; Saporta et al 2003).  It is the mononuclear 
fraction, comprising less than 1% CD34 hematopoietic stem cells, 23% monocytes, and 77% 
lymphocytes (Pranke, et al. 2001), that most commonly constitutes current HUCBC therapy.  
HUCBC and HUCB-derived stem cell transplantation has been therapeutically beneficial 
in rheumatoid arthritis (Liu et al 2010) and neuroinflammatory conditions, including Parkinson’s 
disease (PD) (Ende et al., 2002b) , amyotrophic lateral sclerosis (ALS) (Ende et al., 2000; 
Garbuzova-Davis et al., 2003),  traumatic brain injury (TBI)  (Lu D et al 2002, HIV (for review 
see Petz 2013) and AD (Nikolic et al., 2008).  One study that opened insights into 
immunomodulation by HUCBCs is a study of ischemic stroke in rats (Vendrame et al., 2004), 
which found that HUCBC markedly mediated and improved stroke recovery.  In this study, a 
resultant reduction in brain inflammation—immune modulation and apoptosis in the damaged 
area were credited for this improvement.  Basically, the spleen, a reservoir of immune cells can 
produce pro-inflammatory responses to physical stress and various ischemic injuries, and in so 
doing, cells have been shown to be released (Bakovic et al. 2003; Bakovic et al. 2005; Mebius et 
al., 2005). Furthermore it has been found that following transient occlusion (tMCAO) (Offner et 
al. 2006) and permanent occlusion (pMCAO) in rats (Vendrame et al. 2006) the spleen decreases 
in size and that its removal (Ajmo et al. 2008; Jin et al. 2013; Lee et al. 2008; Das et al. 2011; Li 
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et al. 2011; Walker et al. 2010) is protective in conditions such as pMCAO, tMCAO, 
intracerebral hemorrhage (ICH), and traumatic brain injury (TBI). In the study (Vendrame et al., 
2006) it was found that IV infusion of HUCBCs (1 x 10
7
 cells), 24 hours post-MCAO, may 
thwart MCAO-induced reduction in spleen size; a result that was correlated with sparing of 
stroke-induced ischemic brain injury. While it was shown in an earlier study (Vendrame et al., 
2004) that the injected HUCBCs migrated and persisted briefly in the damaged brain areas, they 
were not differentiating into neurons that could replace those damaged or destroyed by the 
infarct.  Interestingly, in another study (Newcomb et al 2006) the HUCBCs seemed to be 
secreting cell-signaling proteins which, in turn, provided anti-apoptic signaling via Bax 
upregulation and reduced the amount of surrounding inflammation.  In other models 
recapitulating perinatal hypoxic-ischemic brain injury, HUCBCs migration to lesioned brain 
areas directly correlated to reduced infarct size and these cells were detected in the lesioned 
regions up to 7 weeks after the transplantation (Geissler et al.2011; Rosenkranz et al. 2010 and 
2012).  In related studies using hypoxic-ischemic models of brain injury, HUCBC infusion led to 
improvements in lesion-impaired neurological and motor function (Geissler et al. 2011; 
Pimentel-Coelho et al. 2010; Yasuhara et al. 2010).  Moreover, in culture HUCBCs differentiate 
into neural cells (Buzanska et al. 2002; Ha et al. 2001; Neuhoff et al. 2007; Sanchez-Ramos et al. 
2001), but in vivo, cell replacement is uncommon (Garbuzova-Davis et al. 2003; Zigova et al. 
2002).  
In vitro research has shown that HUCBCs are able to secrete growth factors, chemotactic 
proteins and interleukins (Chen et al., 2010; Neuhoff et al. 2007; Newman et al. 2006, 
Rosenkranz et al. 2012).  Additionally in other studies such as those in glioblastoma multiforme, 
HUCBCs release neurotrophic factors that have indirect effects on the damaged tissues of the 
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host (Velpulk et al., 2012) including, most prominently, neuroprotection, anti-inflammation and 
angiogenesis.  Moreover reviews have reported that HUCBC infusion mediates recovery after 
brain injury (Newman et al., 2003; Sanberg et al., 2005) within days, suggesting that in this 
scenario, transplanted cells do not infiltrate the site of brain injury and mediate re-innervation.  
While the underlying mechanisms of the therapeutic benefits of HUCBC - mediated 
improvements remain elusive and likely involve multiple factors, to a large degree, a greater 
number of studies place their focus on these secondary events. 
Specifically, therapeutic benefits derived from HUCBC treatment have been suggested to 
arise from modulation of peripheral inflammatory processes, which in turn affects inflammation 
in the brain parenchyma (Vendrame et al., 2005 & 2006; Sanberg et al., 2005; Taguchi et al., 
2004; for review see Cairns et al., 2003).  Furthermore, in animal models of stroke, HUCBCs 
have been shown to promote a  strong anti-inflammatory T helper 2 (Th2) response (Vendrame 
et al., 2006) as opposed to the deleterious pro-inflammatory T helper cell type 1 (Th1) response.  
Moreover, it has been noted that infusion of HUCBCs reduced the pro-inflammatory 
response induced by stroke, by blocking infiltrating leukocytes and other peripheral immune 
cells (Vendrame et al. 2005).  This decline in the recruitment of macrophage, microglia, and B 
cells to the infarct, downregulated expression of pro-inflammatory mediators like IL2, TNF-α, 
and IL-1β, subsequent to the stroke event (Vendrame et al. 2005).  Modulation of inflammatory 
effector cells by HUCBC was also implicated in the spleen following stroke.  Following 
intravenous infusion, roughly 1% of HUCBCs migrated to the spleen post middle cerebral artery 
occlusion (MCAO) (Chen et al. 2001).  In another significant HUCBC study, stroke pathology 
was significantly reduced by the reduction of immune cell activation (Vendrame et al. 2006) and 
thus contributed to reducing neurodegeneration.  At single high doses in AD preclinical models, 
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administration of these cells to the PSAPP mice was even linked to an extension of lifespan 
(Ende 2001).  Consequently, HUCBCs not only act at the CNS level, but also manipulate and 
suppress the immune/inflammatory cascade, following an ischemic insult 
Another potential mechanism by which HUCBC have been proposed to confer 
therapeutic benefit is via modulation and mobilization of endogenous adult stem cell populations 
(Bachsteter et al 2008; Taguchi et al., 2004).  In addition, HUCBCs may promote reductions in 
amyloidosis through several indirect mechanisms.  HUCBCs, for example, produce a number of 
neurotrophic factors, including nerve growth factor (NGF), colony stimulating factor-1 (CSF-1), 
thrombopoietin, and the anti-inflammatory cytokine, interleukin (IL)-11 (Newman et al. 2006, 
Arien-Zakay et al., 2011).  Conversely, HUCBCs downregulate the pro-inflammatory cytokines 
including tumor necrosis factor- (TNF-) and IL-1β (Vendrame et al., 2005) all of which can 
contribute to the production of amyloidosis (He et al., 2007; Vandenabeele et al., 1991).   
 
HUCBC-therapy in various models of disease  
 
 When the CNS is presented with an insult, intraparenchymal inflammation and activation 
of systemic immunity is triggered.  The overall effect has the capacity to exacerbate 
neuropathology and stimulate mechanisms of tissue repair (Donnelly et al. 2008).  Although our 
understanding of the mechanisms that regulate these divergent functions is incomplete, immune-
based therapies are becoming a therapeutic focus.  Benefits derived from HUCBC treatment have 
been suggested to arise from modulation of peripheral inflammatory processes, which in turn 
affects inflammation in the brain parenchyma (Vendrame et al., 2005 & 2006).  Infusion of 
HUCB cells have been reported to reduce the pro-inflammatory response induced by stroke, by 
blocking infiltrating leukocytes and other peripheral immune cells. Another reported benefit is 
that HUCBCs also promotes cellular repair and therefore cell survival (Rosenkranz et al., 2012; 
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Rowe et al., 2012).  Furthermore, HUCBCs therapy has been used in tissue engineering and in 
several disease models in regenerative medicine (Harris et al., 2007). 
 
Stroke/ brain ischemia and cell survival  
 Apart from being the leading cause of disability, stroke is the fourth leading cause of 
death worldwide.  Beginning in 2001 (Chen et al. 2001), the most promising HUCBC therapy 
has been in the area of stroke.  While it could reverse behavioral and physical decline (Chen et 
al., 2001), the HUCBCs need not be infused into the target organ (Willing et al., 2003).  In 
animal models of stroke, HUBC have been shown to promote a  strong anti-inflammatory T 
helper 2 (Th2) response (Vendrame et al., 2004) as opposed to the deleterious pro-inflammatory 
T helper cell type 1 (Th1) response.  Interestingly this observation was seen in conjunction with 
reduced infarct volume and very importantly with rescue of behavioral deficit (Vendrame et al, 
2004) 
 Protein Kinase B (PKB) also known as AKT is a serine/threonine-specific protein kinase 
and has been known to protect neural cells.  It is believed that HUCBCs secrete soluble factors 
(ligands) that bind to and activate the AKT survival pathway resulting in an inhibition of 
apoptosis. AKT activation also mediates gene regulation and protein expression which aids in 
cellular repair and therefore cell survival.  More specifically, in ischemic injury, these HUCBC 
soluble factors activate AKT, upregulating peroxiredoxin 4 (Prdx4) expression which has the 
overall effect of increased cell survival of oligodendrocytes (Rowe et al., 2012).  
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Spinal cord injury 
 One of the studies that showed that HUCBCs can improve motor behavior deficits in rat 
SCI model and also made inroads in the observance that HUCBCs migrate to sites of injury in 
the spinal cord but not to the contralateral side was a report from Saporta et al. 2003.  Briefly, 
pre-labeled HUCB cells (with FITC-conjugated cholera toxin) were intravenously injected either 
1 or 5 days following SCI that was induced by unilateral hemicompression with an aneurysm 
clip for 1 minute. Open field behavior at 1, 2, and 3 weeks after treatment was used to determine 
behavioral recovery. It was also observed that cohort rats that received HUCBCs at 5 days after 
surgery showed significant improvement over those 1 day post-surgery. While 
immunohistochemistry (IHC) showed that these cells migrated to the injured site, no cells were 
observed in the intact spinal cord or in necrotic areas. Additionally and reflective of this study’s 
behavior data, approximately double the number of viable cells homed to the injured spinal cord 
when infused at the 5 day time point compared to the 1 day time point. In spinal cord injury 
(SCI) models, it is believed that systemic administration of HUCBCs promotes the recovery of 
hind limb function through stimulating the production of IL-10, glial cell-derived neurotrophic 
factor (GDNF) and vascular endothelial growth factor (VEGF) (Forostyak et al 2013).  Systemic 
administration of HUCBCs stimulated production and secretion of the anti-inflammatory 
cytokine, IL-10, by supressing tumor necrosis factor- α (TNF-α) and other pro-inflammatory 
cytokines (Rainsford et al., 2002).  HUCBCs also stimulated production of both VEGF and 
GDNF in the injured spinal cord suggesting that HUCBCs may promote an environment 
conducive to revascularization of the ischemic spinal cord, facilitating neuronal regeneration 
(Chen et al., 2008). 
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Amyotrophic lateral sclerosis (ALS) 
 Activation of microglia and astrocytes are key components of ALS pathology. This 
neuroinflammation is a direct cause of neuron death (Appel et al., 2008; Zhao et al., 2010).    By 
using a high intravenous dose administration (3.5 x 10
7
 cells) of HUCBC mononuclear cell 
(MNC) (MNC HUCB), Ende et al., 2000 reported a significant lifespan increase in their studies 
with ALS mice. The exact mechanism of HUCBC therapeutic benefit is unclear.  Some studies 
believed that the systemically delivered of HUCBCs not only migrates into CNS 
injured/damaged areas but they express neural-like markers without pre-exposure to specific 
factors.  It is thought that in response to signals from cytokines and cell surface receptors and 
antigens, or a compromised BBB, these cells enter the brain.  Once present in the 
microenvironment of the brain after injury, HUCBCs may be driven into a neural cell phenotype 
(Garbuzova-Davis et al., 2003). In other studies it is thought that neuron protection and slowing 
of the disease is achieved when HUCBCs act to adjust the ALS-specific microenvironment, 
namely, that various factors secreted by the cells, rather than differentiation or cell-cell contact 
mechanisms, are the main therapeutic mediators (Garbuzova-Davis et al., 2012). These cells may 
have their effects by cleaning the toxic microenvironment in the area of the injured neurons 
rather than by their migration to injured areas and subsequent replacement of dying neurons. 
 
           Alzheimer’s disease (AD) 
 HUCBCs may promote reductions in amyloidosis through several indirect mechanisms as 
well.  For example, they produce a number of neurotrophic factors, including nerve growth 
factor (NGF), colony stimulating factor-1 (CSF-1), thrombopoietin, and the anti-inflammatory 
cytokine, interleukin (IL)-11 (Arien-Zakay et al., 2011).  Conversely, HUCBCs down regulate 
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the pro-inflammatory cytokines including tumor necrosis factor- (TNF-) and IL-1β 
(Vendrame et al., 2006).  Thus, therapeutic effects of HUCBC infusion in PSAPP mice might 
result from this beneficial immune modulation in the periphery, suggesting that the overall 
improved immune system of the mice caused the reduction of the amyloid in the brain (discussed 
more in Chapter 5).  
 
Monocytes subsets and recruitment in AD 
 Significantly HUCBCs have been shown to have therapeutic benefit in a plethora of 
disease conditions.  However there is increasing evidence in some malignancies that tumor cells 
can originate from rare stem cells, which are responsible for maintaining the tumor (Rossi et al., 
2006).  As such the infusion of complete HUCBCs (95 - 98% mononuclear cells) could actually 
promote tumorigenesis in this manner by increasing the repertoire of potentially tumorigenic 
cells.  Monocytes, part of the immune system, which undertake immune surveillance and are 
very successful in removing dead cells and other cellular debris (Seta et al., 2007), represent a 
potential source for therapeutic intervention. 
        Bone marrow’s myelomonocytic stem cells give rise to peripheral blood monocytes which 
are released on demand into the blood (Auffray et al., 2009; Gordon et al, 2005; Swirski et al., 
2009).  These monocytes can be precursors to the macrophage and other antigen presenting cell 
(APC) (Fogg et al., 2006; Seta et al., 2007).  Upon entering tissues and contingent on the 
microenvironment and their location in the body, circulating blood monocytes differentiate into 
various types of resident macrophages (Geissman et al., 2003; Bosco et al., 2008).  Monocytes 
and macrophages play a key role is innate immunity as they are able to protect against pathogens 
through phagocytosis and cellular cytotoxicity (Bosco et al., 2008).  
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 Additionally it is well-known that upon release from the bone marrow (BM) into 
peripheral blood, monocytes differentiate into distinct subsets; possibly due to their respective 
arrays of chemokine receptor expression.  Broadly, differential expression of CD14 (expressing 
CCR2 and part of the lipopolysaccharide (LPS) receptor) and CD16 (expressing higher MHC II, 
CD32 and CCR5 and also known as FcγRIII) allow monocytes to be divided into two major 
subsets (Passlick et al., 1989): the "classical" monocytes, that represent the majority of 
circulating monocytes, and the non-classical monocytes that patrols the vasculature for 
maintenance of tissue integrity and repair.  This phenomenon is conserved in both human and 
mouse and is reflective of expression of receptor and surface marker profile (phenotype), and 
function (Ziegler-Heitbrock 2007; Geissman et al., 2003).  More specifically, while the classical 
monocyte subset comprise of Gr1+/CD43−/CD62L+/CX3CR1low/CCR2+/VEGFR1high cells in 
the mouse and CD14
high
/CD16−/CD62L+/CX3CR1low/CCR2+/VEGFR1high cells in the human, 
non-classical monocytes comprise of Gr1−/CD43+/CD62L−/CX3CR1high/CCR2−/VEGFR1low 
cells in the mouse and CD14
low/CD16+/CD62L−/CX3CR1high/CCR2−/VEGFR1low cells in the 
human (Weber et al., 2000; Czepluch et al., 2011; Grage-Griebenow et al., 2001; Ziegler-
Heitbrock et al., 1992; Ancuta et al., 2009).  The CD14+/CD16+ cells prompted by pathogens or 
tissue damage in the host are characterized as pro-inflammatory based on higher expression of 
pro-inflammatory cytokines and higher potency in antigen presentation (Ziegler-Heitbrock et al., 
1993).  The CD14+/CD16− cells prompted by vascular damage are characterized as being anti-
inflammatory and aid in revascularization and tissue healing (Magga et al., 2012).   
 According to the amyloid cascade hypothesis (McGeer et al., 2013; Hardy et al 2002), β-
amyloid, is believed to initiate the catastrophic sequence of events in AD.  While microglia, 
discussed elsewhere, are postulated to have a role in clearance of Aβ and subsequently regulation 
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of AD pathogenesis (McGeer et al., 2013; Rogers et al., 2002;  D’Andrea et al., 2004; Wilcock et 
al., 2004; Mandrekar et al., 2009; Floden et al., 2006), converging evidence  indicates that 
microglia clearance ability diminishes with age and AD progression.  Moreover it was found 
despite continued activation and eventual recruitment of microglia into Aβ plaques to 
phagocytize, Aβ aggregation still increased (Hickman et al., 2008).  Although it is speculative as 
to how endogenous microglia repopulate, reports indicate that certain peripheral monocytic cell 
populations have the potential to not only cross the BBB but also to infiltrate into the 
parenchyma of the brain (Simard et al., 2004; Kennedy et al., 1998).  Furthermore, this 
occurrence has been observed in AD.  It is believed that these monocytes effectuate plaque 
clearance either by impeding its aggregation or by reducing existing plaques (Lesbon et al., 
2010; Malm et al., 2005).  
One thought is that BM-monocytes cross the BBB and hone into the brain during Aβ 
aggregation.  A study of Aβ plaques in APPSwe mice supported this hypothesis whereby it was 
found that while most plaques were blood-vessel associated, very interestingly it was observed 
that monocyte populations were present where Aβ/blood vessel interfaced (Wegiel et al. 2003). 
A 7 month study using 6 week-old PSAPP AD mouse model showed that when BM cells from 
GFP1 transgenic mice were transplanted into chemotherapy-myeloablated mice (GFP-APP/PS1 
chimeric), copious amounts of GFP1cells were observed throughout the CNS, with a higher 
concentration in the hippocampus and cortex and around circumventricular organs compared to 
no CNS GFP1 cells in WT littermate controls (Lampron et al., 2013).  These cells were found in 
the immediate vicinity of amyloid plaques, hence supporting the claim that BM myeloid cells 
can be induced to enter the CNS based solely on amyloid deposition.  In another  study where 
various Aβ isoforms and  BM-derived cells were infused  in irradiated APP23 transgenic AD 
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mice, it was found that not only could the BM- derived cells cross the BBB but that 20% of the 
cells are associated with congophilic plaques (Simard et at., 2006).  Furthermore, of the A 
isoforms injected, Aβ42 and Aβ40 had the ability to activate genes associated with inflammation, 
like monocyte chemoattractant protein -1 (MCP-1) and IL-1β, and more significantly, to initiate 
blood-derived monocyte infiltration. While only 2% of BM comprises monocytic populations, 
monocytes from adult peripheral blood represent a significant population of ~ 10% (Gordon et 
al., 2005).  In myeloablative treatment of malignant and non-malignant diseases of the blood, 
BM-derived and HUCBC-derived MNCs are currently the most commonly used resource.  While 
BM-derived cells and HUCBCs proffer effective treatments, for reasons discussed elsewhere in 
this chapter, HUCBCs are considered superior.  HUCB-derived mononuclear cells, as treatment 
targets in AD, are thought to have vast therapeutic benefit because of their potential role in Aβ 
progression and phagocytosis.  While the precise underlying mechanisms of peripheral 
mononuclear infiltration across the BBB into the CNS have not been unanimously decided, an 
understanding of their contribution to AD pathogenesis is important as this advances 
development of therapeutic Aβ targeting. 
 
Specific aims              
         Previous studies from our laboratory showed that HUCBC-infused PSAPP mice experience 
a marked reduction of A/-amyloid plaques with lowered hyperphosphorylated tau protein and 
Cerebral Amyloid Angiopathy (CAA) (Obregon et al., 2008).  Most importantly, these effects 
are associated with: (a) decreased microglial CD40 expression, (b) increased serum Aβ levels, 
(c) decreased sCD40L serum levels, and (d) elevated CNS/serum levels of anti-inflammatory 
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cytokines. We also showed a reduction in Aβ levels/β-amyloid pathology and associated 
astrocytosis following low-dose infusions of HUCBCs in Alzheimer mice (Nikolic et al., 2008). 
        While these results taken together with our previous finding that crossing Tg2576 mice with 
CD40L null mice or treating PSAPP mice with CD40L antibody reduced Aβ loads and 
microgliosis and improved cognitive function (Tan et al., 2002; Roach et al., 2004) were 
encouraging, speculation arose as to how effective were they in terms of cognitive function in the 
PSAPP AD transgenic model. We thought to explore cognitive recovery by using the cognitive 
function RAWM test; and to examine balance performance by using the locomotor rotarod  test.  
Our previous data along with our interest to develop on the therapeutic benefits achieved from 
those studies led us to hypothesize that multiple low-dose injections of HUCBCs improve 
cognitive impairment and reduce Aβ-associated neuropathology in PSAPP Alzheimer mice.  
        Specifically we proposal to explore the following specific aims: 
Specific Aim 1. Investigate bio-distribution of HUCBC transplantation in PSAPP mice.  
Specific Aim 2. Characterize efficacy and determine therapeutic outcome of HUCBC following 
short and long term multi injections at early and late disease stages in PSAPP mice.  
Specific Aim 3. Determine AD-like pathological and cognitive changes associated with multiple 
HUCBC-Derived monocyte injections in PSAPP mice. 
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CHAPTER TWO 
Materials and methods 
 
Animals and institutional approval  
 PSAPP mice of a hybrid B6/SJL background (Jankowsky et al., 2001; Garcia-Alloza et 
al., 2006) were used in all experiments of the study.  No human research was involved.  For the 
cord blood experiments, 7 month old PSAPP transgenic mice, with mutations in human APP and 
PS1 (Jackson Laboratory, Bar Harbor, ME), and 7 month old Sprague-Dawley rats (Harlan 
Laboratories) were maintained on a 12 hour-light/12 hour-dark cycle at ambient temperature and 
humidity.  All cohorts were housed in the animal facility at the University of South Florida, 
Morsani College of Medicine (Johnnie B. Byrd Sr. Alzheimer’s Center and Research Institute, 
Tampa, FL, USA).  They were allowed standard rodent chow and water ad libitum.  Previous 
studies suggest that Aβ accumulation in transgenic mouse models of AD is accelerated under low 
testosterone conditions and reduced in the presence of high testosterone or dihydrotestosterone 
(McAllister et al., 2010; Rosario et al., 2006) and that females show earlier onset and larger 
plaque load than males (Wang et al., 2003).  However, in order to model a realistic human AD 
population, both males and females were used in this study.  For the cord-blood derived 
monocyte experiments, 5 month old PSAPP mice were used. All cohorts were male and this 
served to eliminate the possibility of gender differences among groups.  All animals in these 
experiments were observed in a blinded, randomized approach.  All procedures described herein 
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were in accordance with the animal protocol approved by the University of South Florida (USF) 
Institutional Animal Care and Use Committee.  
 
HUCBCs preparation  
 HUCBCs (95 - 98% mononuclear cells) were donated by Saneron CCEL Therapeutics 
Inc. (Tampa, FL).  Saner on used de-identified cord blood donations from commercial sources 
for the processing of the HUCBC. Briefly, the mononuclear fraction (U-CORD-CELL
TM
) was 
obtained from donated cord blood using a proprietary density gradient solution (DSS-001) 
developed by Saneron and GE Healthcare.  Purified HUCBC were cryopreserved and stored in 
liquid nitrogen at -210
o
C.  Prior to transplantation, HUCBCs were thawed at 37°C for 4 minutes, 
washed in Phosphate Buffered Saline (PBS), assessed for cell quantification and viability (Ellyn, 
Vi-CELL) and suspended in PBS to achieve a final desired cell concentrations of 1 - 2.2 x 10
5
 
cells per 100 µL for each transplant. 
 
HUCBCs, HUCBC-derived monocyte transplantation 
HUCBCs infusion 
        Cord blood (1 mL) was removed from liquid nitrogen and thawed in a 37°C water bath for 4 
minutes.  Twenty (20) L of HUCBC was removed and this constituted recovered samples (i.e. 
whole HUCBC without washing): 10L assayed for automated cell count via CellDyne and 10 
L assayed for automated cell viability via Vi-CELL.  The remaining HUCBCs were then 
pipetted into 10 mL of cold PBS and centrifuged for 15 minutes at a speed of 400 relative 
centrifugal force (RCF) at 4°C.  The cells were re-suspended in 10 mL of PBS and washed.  The 
pellet was re-suspended in 1 mL of PBS and 20 uL removed for automated “washed samples” 
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cell counts and viability assays of the washed samples.  Cells were centrifuged, re-suspended in 
PBS and aliquoted to 1 x 10
5
 cells per 100 L dose per mouse or to 2.2 x 105 cells per 100 µL 
dose per rat. Previous work in a rat model of stroke has shown that single high HUCBC infusion 
(1x10
7
 cells, p<0.01; 3 to 5x10
7
 cells, p<0.05) results in significant reduction in infarct volume 
as well as rescue of behavioral deficits associated with decreased proinflammatory cytokine 
production (Vendrame et al., 2004).  
        The right tail vein was identified and vasodilated using warm water.  For determination of 
HUCBC biodistribution, 18 seven-month-old PSAPP mice and 18 non-transgenic Sprague-
Dawley rats were randomly injected in the right tail vein with HUCBCs at 1 x 10
5
 or 2.2 x 10
5
 
cells/100 μL, respectively, using a 27 gauge needle attached to a 1 mL syringe.  Animals were 
sacrificed and blood, hind limbs, liver, lung, spleen, kidney, heart, spinal cord, brain, and gonads 
were collected at 24 h, 7 or 30 days for PCR analysis of human DNA.  For determination of 
HUCBCs on AD pathology and behavioral deficit, 6 mo old PSAPP mice or their WT littermates 
were treated with 1 x 10
5
 cells/100 μL per mouse (treatment group, n = 20, 10 ♀/10♂) or 100 µL 
PBS per mouse (control group, n = 10, 5♀/5♂), delivered into the right tail vein. This treatment 
was repeated biweekly for the first month and monthly thereafter for 6- or 10 months.  Mice 
were kept in shared cages with ad libitum water and food and randomly assigned into the 
following 4 groups: Group 1 (n = 5, PSAPP/PBS), Group 2 (n = 10, PSAPP/HUCBCs), Group 3 
(n = 5, WT/PBS) and Group 4 (n = 10, WT/HUCBCs).  All animals survived for the entirety of 
the transplantation period.  
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HUCBC-derived monocyte infusion 
 For HUCBC-derived monocytes and monocyte-deficient HUCBC transplantation, 
subsequent to obtaining quantification and viability data (see above), the HUCBC suspension 
was centrifuged and re-suspended in monocyte buffer, containing 0.5% BSA, and 2 mM EDTA 
in PBS.  Monocytes were separated using the MACS Miltenyi biotec CD14 MicroBeads human 
kit (Vitale et al., 2004).  CD14 MicroBeads were added to the cell suspension and incubated in 
the refrigerator for 15 minutes.  Cells were then washed, re-suspended in buffer and run through 
a column in a magnetic separator. Cells were allowed to flow into a collection flask which then 
comprised the monocyte-deficient cord blood to be infused in the cohorts.  The column was 
removed and flushed with buffer to obtain an enriched population of cord blood derived 
monocytes.  Subset monocyte populations were characterized using flow cytometry. HUCB-
derived monocytes were stained for identification of monocyte subsets using monoclonal 
antibodies to CD16+ and CD14+ (Sigma-Aldrich).  Monocyte population comprising of   ~95% 
of the CD14+ subset were used in the study. Cell counts and viability were then carried out as 
described. Cells were centrifuged, re-suspended in PBS twice and aliquots of 1 x 10
6
 cells per 
100 µL concentration per mouse were made. 
The injection of HUCBC-derived monocytes and monocyte-deficient HUCBC was 
performed as described for HUCBCs except that 1 x 10
5
 cells/100 μL Complete Cord Blood 
(CB-W), Cord Blood derived Monocytes (CB-DM) or Monocyte deficient Cord Blood (MD-CB) 
per mouse (n = 24 ♂; 8 per treatment group) or 100 µL PBS (control, n = 8: 8♂) were delivered 
via the right tail vein.  PSAPP and WT mice were randomly assigned into the following 8 
treatment groups: Group 1 (n = 6, PSAPP/PBS), Group 2 (n = 6, PSAPP/MD-CB), Group 3 (n = 
6, PSAPP/CB-W), Group 4 (n = 6, PSAPP/CB-DM). Group 5 (n = 2, WT littermate/PBS), 
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Group 6 (n = 2, WT littermate/MD-CB), Group 7 (n = 2, WT littermate/CB-W) and Group 8 (n 
= 2, WT littermate/CB-DM).  (Please refer to the explanation for the number of controls in 
section 2.3.1) 
 
PCR analysis  
 The presence of human DNA in rodent tissues was used as a screen to determine the bio-
distribution of HUCBCs in murine models.  Total purified DNA was obtained from organ 
samples collected from PSAPP mice and Sprague-Dawley rats, using a commercially available 
DNeasy Blood and Tissue kit (Qiagen, Valencia, CA), and quantified using a NanoDrop 2000C 
spectrophotometer (ThermoFisher).  Fresh DNA isolated from HUCBCs immediately removed 
from cryopreservation was used as a positive sample to determine the band location for human 
glycerol-3-phosphate dehydrogenase (HG3PDH).  DNA was replicated using common PCR 
techniques (0.5 μg/25 μL final reaction volume) using a commercially available kit (HotStarTaq 
Master Mix; Qiagen, Valencia, CA, USA) in accordance with the manufacturer’s instructions, 
and specifically for the presence of the HG3PDH, fragment size of 100 bp (genbank reference 
for whole human HG3PDH AH006637.1 gene) using appropriate primers (sense: 5’-
GGCTGGGACTCATGGAGAT-3’; and antisense primer: 5’-CGGGTAAGTCGTTGA-
GAAAG-3’).  While studies have shown these primers to be specific and effective (Vendrame et 
al., 2004), prior to our experiments, we conducted validation checks to ensure that not only 
would they generate a single band but that the product would be of the correct size  (human 
genomic DNA ~100 BP)  for analysis and not rodent genomic DNA.  Primers were confirmed 
using Basic Local Alignment Search Tool (BLAST) searches that are used to identify areas that 
are similar between sequences.  In brief, the sequencer program makes a comparison of 
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sequences from nucleotides or proteins with sequence databases and analyzes the statistical 
significance of matches that are recognized. Spleen tissue from the negative control animals 
(PBS treated) was used as the negative control for the gel at each time point. Cord blood, 
representative of human genomic DNA (~100 BP) was used as a positive control. Thermocycler 
conditions consisted of an initial denaturing step at 95 °C for 15 minutes, followed by 35 cycles 
of 94 °C for 30 seconds, 50 °C for 1 minute, and 72 °C for 1 minute, and a final extension step at 
72 °C for 10 minutes.  DNA presence in the various organs was resolved using ethidium 
bromide-stained agarose gel (1%) electrophoresis and identified using UV transillumination by 
comparisons with molecular weight markers (Invitrogen). 
 
Motor activity and cognitive tests 
 PSAPP transgenic mice and their WT littermates underwent tests for motor activity, (the 
rotarod test), and cognitive ability, (the radial arm water maze (RAWM) test and the visible 
platform in an open pool test).  Evaluations were conducted every month for the 6 and 10 month 
treatments in the HUCBC experiments and at 7.5 and 9.5 months of age in the HUCBC derived 
monocyte experiments. 
 
Rotarod locomotor test 
In some cases of AD, there have been reports of ataxia and apraxia (Chainay et al., 2006; 
Derouesné et al., 2000; Della et al., 2004; Herbert et al., 2010).  The main objectives of the 
rotarod locomotor test were to observe motor coordination and to exclude the possibility that 
positive effects of any treatment in the cognitive tasks were due to differences in sensorimotor 
ability.  The rotarod test was performed for two consecutive days.  Mice were positioned on the 
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rod (diameter 3.6 cm) of the equipment (Rotarod 7650 accelerating model, Ugo Basile, 
Biological Research Apparatus, Varese, Italy) to gauge differences in balance, motor learning 
and coordination, accomplished by measuring the balance and coordination of fore and hind 
limbs.  The rod on the apparatus was set at 4.0 rpm and mice were placed, five at a time, in an 
assigned location on rod.  The rod was allowed to steadily accelerate from 4.0 rpm up to 40.0 
rpm over a 3-minute session.  Evaluation of each mouse was made by monitoring clinging from 
the top of the rotating barrel or by latency to fall, that is, the time taken for the mouse to fall off 
the rotating rod under a continuous acceleration. Fallen mice and those that stayed on the rod 
throughout the 3-minute trial were then removed and allowed to rest for 30 minutes before 
returning to complete the remaining three trials of the test yielding  a total of four trials on day 
one.  This was repeated on day two.  Mice training occurred in one trial and this was adequate to 
attain a performance baseline and to establish habituation.  As a precautionary measure against 
physical damage from potential falls, a soft pad was placed under the equipment. 
 
RAWM test 
 The RAWM is used to examine learning and memory deficits in transgenic mouse.  This 
test also optimizes sample size requirements when compared to other typical rodent memory 
tasks (Arendash et al. 2001).  Additionally, the RAWM was our cognitive test of choice because 
it encompasses the better of two well-known tests without the adverse treatment of the animal.  
The RAWM presents both the use of spatial cues and the ease of measurement of the dry radial 
arm maze pooled together with the merits of the Morris water maze robust motivation and brisk 
learning.  This approach highlights the discriminating memory dysfunction in amyloid precursor 
protein (APP) transgenic mice (Haiso et al., 1996; Puolivali et al., 2003; Jankowsky et al., 2005).  
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These benefits necessitate no motivational elements such as food deprivation or foot shock.  The 
RAWM has an open centralized region that extends into six swimming lanes or arms (Alamed et 
al., 2006).  An escape platform located at the end of one of the lanes is referred to as the goal 
arm.  All cohorts received two days of 15 swims or trials per day. Each swim culminated either 
when the visible or submerged goal was located or after 1 minute had elapsed.  Briefly the mouse 
was dropped into a random start arm (predetermined on a score sheet) and allowed to swim until 
it located and climbed onto the platform (goal) over a period of one minute.  If the platform was 
not located at the end of the 60s, the experimenter guided the mouse to it and the mouse was 
allowed to remain on the platform for 30s to process visual cues.  Once the platform was found, 
either by self-discovery or by guidance, the mouse was allowed to rest there for 15 seconds.  
Subsequently, the mouse was then removed, towel dried, and placed in its cage with a heat lamp 
slightly overhead for a 30-minute rest period.  Consequently, another mouse was selected and the 
process repeated until all mice were tested. Errors were recorded as any entry into an incorrect 
arm.  Errors also accrued when the mouse failed to enter any arm for the initial15 seconds of the 
trial.  For the first day, animals underwent a 15 trial training that interchanged between a visible 
and a submerged platform, in the goal arm.  The second day also involved a 15 trial testing, but 
with only the hidden platform.  For each trial, while the location of the goal arm for a particular 
animal remained the same, the start arm changed.  Results were analyzed as number of errors 
made.  
 
Visible platform in an open pool swim test 
 This test was conducted during the last day of the test set, to examine whether the 
animals possessed the skills sufficient to complete the water maze task.  In brief, it was 
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performed in the same pool as the RAWM, however, the triangular wedges were removed and 
the pool was left open with a visible platform in an imagined quadrant.  This platform has 
insignias which are visible above the water, while the platform remains slightly below the water 
(Alamed et al., 2006).  For each trial, the mouse was dropped in the same start location, while the 
goal was placed in a different location per each mouse.  Here, just as in the RAWM test, each 
mouse was tested and latency to reach the platform was recorded.  The test ran for 15 trials.  
Mice were considered as having a possible swimming or visual defect if they had not 
accomplished reaching the platform within the 20-second latency criterion for the last 3 trials of 
the visible platform task and were thus excluded. None of the cohorts were excluded in this 
study. This test was used to verify that all mice were able to both see and climb the platform. For 
the open pool test, all visual cues were removed from the room so the mice relied only on their 
sight to find the platform. Latency to find and ascend the platform was recorded (60 seconds 
maximum). Latency was recorded over number of errors made as all cues were visible and in 
addition there were no physical lanes to impede field of vision.  
 
Tissue preparation 
After all neurocognitive testing was completed, mice were euthanized at either 6- or 10-
months after transplantation with isofluorane anesthesia and then transcardially perfused with an 
ice-cold physiological buffered saline (PBS) containing heparin (10 U/mL).  Prior to transcardial 
perfusion, hind limbs (for bone marrow) and 500 µL peripheral blood were collected.  Brains 
were rapidly isolated and halved sagitally using a mouse brain slicer (Muromachi Kikai, Tokyo, 
Japan) and the left hemispheres were frozen immediately in liquid nitrogen and stored at −80°C.  
For molecular analysis, the left hemispheres were sonicated in RIPA buffer (Cell Signaling 
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Technology, Danvers, MA) and centrifuged at 14,000 rpm for one hour at 4°C.  Supernatant was 
transferred to a new tube for soluble Aβ analysis and the pellet was used for insoluble Aβ 
extraction as described previously (Tan et al., 2002).  The right hemispheres were placed in 4% 
paraformaldehyde in 0.1 M PBS at 4°C for 24 hours, and then transferred to a graded series of 
sucrose solutions (10, 20, and 30%, each at 4°C for 24 hours) before being encased in tissue 
freezing medium for cryostat sectioning.  Sequential 25 μm coronal sections were cut and free-
floating sections were then stored at 4°C in 24-well plates containing PBS with 0.01% sodium 
azide. 
 
Immunohistochemical analysis 
 Immunohistochemical staining was performed using mouse monoclonal anti-human 
Aβ17-24 antibody (clone 4G8, Covance Research Products, Emeryville, CA) for amyloid 
pathology, and using monoclonal mouse anti-human CD45 antibody (LCA) (Abcam, Cambridge, 
MA) for microglial activity in conjunction with the VectaStain Elite ABC kit (Vector 
Laboratories, Burlingame, CA) coupled with diaminobenzidine substrate.  Brains were sectioned 
coronally giving the advantage of viewing the whole brain from front to back.  For quantitative 
histological procedures, all sections collected were permitted unbiased sampling of every 12
th
 
section throughout the brain giving ample depth that reflected regions throughout the whole 
brain.  Briefly, immunohistochemistry was performed on free-floating sections in 24-well plates. 
After three 5-minute washes in PBS, sections were blocked for an hour at room temperature with 
agitation in 5% horse serum in PBS (blocking buffer). Sections were incubated with the primary 
antibody overnight at 4°C, washed three times in PBS and then incubated in biotinylated 
secondary antibody for 1 hour. The avidin-biotin complex (ABC) was added to the sections for 
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30-40 minutes and then 1.4 mM 3-3’-diaminobenzidine with 0.03% hydrogen peroxide in PBS 
was used as the chromogen. This final peroxidase reaction was for approximately 3 min. 
Sections were mounted on Superfrost slides (Fisher Scientific) then air-dried for 24 hours. 
Sections on slides were washed and dehydrated by rinsing through two 2-minute changes of 95% 
ethanol, two 2-minute changes of 100% ethanol and clearing through three changes of xylene. 
Slides were then cover-slipped with Permount (Thermo Fisher Scientific). Aβ burden and CD45 
presence were determined by conventional quantitative image analysis.  Images were acquired as 
tagged-image format files to retain maximum resolution using an Olympus BX-53 microscope 
and digitized using CellSens Standard imaging software (Olympus).  
        All images that are presented and used for quantification were collected using 4X 
magnification. To obtain stained positive area and to ensure that there was no regional bias in the 
values, four anatomical regions of interest  (one region of the entorhinal cortex and three regions 
of the hippocampus) of five sections (an average of 5 total counts for entorhinal cortex and of 15 
total counts for hippocampus) were used with 4  number of animals per treatment group Digital 
images were routed into a Windows PC for quantitative analyses using Image J software (NIH) 
to quantify the percent area occupied by positive stain. The colored pictures taken were switched 
to black/white photographs. The field was manually edited to remove artifacts. A threshold 
optical density was configured to regard as plaque, any area of coloration that passed a certain 
dark hue and that region was considered as positively stained. Colorations under that 
predetermined threshold was not judged to be plaque but was considered background. Thus four 
images on the 25-µm of hippocampus and entorhinal were captured and a threshold optical 
density was obtained that discriminated staining from background.  Quantitative image analysis 
for the percentage of Aβ 4G8 immunoreactive plaques from hippocampal brain regions and of 
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CD45 positive cells in the entorhinal cortex regions were determined. Data are reported as 
percentage of positive immunolabeled occupied area captured relative to the full area captured 
(positive pixels divided by total pixels captured). Quantitative image analysis was performed by 
a single examiner, blinded to sample identities.  
 
Enzyme-linked immunosorbance assay (ELISA)  
            Aβ40, 42 was quantified in all samples using Aβ40 and Aβ 42 ELISA kits (Invitrogen, 
Camarillo, CA) in strict accordance with manufacturer’s instructions and as described previously 
(Tan et al., 2002; Rezai-Zadeh et al., 2005).  Half brains were sonicated in 1mL ice-cold lysis 
buffer (2.5 mM sodium pyrophosphate, 20 mM Tris, pH 7.5, 1 mM EGTA, 1% v/v Triton X-
100, 1 mM PMSF, 150mM NaCl, 1 mM EDTA, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 
µg/mL leupeptin) for 10 seconds and incubated for 5 minutes on ice, for a total of 3 repetitions, 
to prepare samples for the detection of Aβ40, 42 by ELISA.  Collected lysates were then 
ultracentrifuged at 14,000 x g for 15 minutes at 4°C.  Prior to plating, protein levels in cell lysate 
supernatants were determined and normalized by bicinchoninic acid assay (BCA; Thermo Fisher 
Scientific, Waltham, MA) in accordance with the manufacturer’s instruction.  Samples were 
further diluted by 1:20 for soluble Aβ40, 42 following manufacturer’s instruction.  Standards, 
supplied in the ELISA kits, and the normalized diluted samples were added to pre-coated 96 well 
ELISA plates.  Detergent-insoluble Aβ40, 42 were detected in brain homogenates by acid 
extraction of pellets using 1mL of 5 M guanidine HCl buffer (Johnson-Wood et al.,1997).  These 
insoluble Aβ40, 42 samples (dilution of 1:4000) were then added to 96 well pre-coated ELISA 
plates.  Values obtained were reported as % control or pg of Aβ1-x/mg of total protein. 
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Western blot analysis 
Following the sample preparation as described above, an aliquot corresponding to 40 μg 
of total protein was electrophoretically separated using 10% Tris-SDS polyacrylamide gels or 10 
- 20% Tris/tricine gels (Bio-Rad, Richmond, CA) and transferred to polyvinylidene fluoride 
membranes (Bio-Rad) previously washed in distilled de-ionized water (ddH2O).  As a positive 
control, Aoligomers were prepared from synthetic human A42 according to published 
methods (Walsh et al., 2000; Lesné et al. 2006; Zhu et al., 2011) whereby the A42  peptide was 
dissolved in hexafluoroisopropanal (HFIP) (Sigma-Aldrich, St. Louis, MO) to 1mM and stored 
at -20°C  as a dried HFIP film after evaporation of the solvent. The dried peptide was 
resuspended in anhydrous Dimethyl sulfoxide (DMSO) to a final concentration of 5 mM, diluted 
with ice-cold phenol red-free F-12 cell culture media (with L-Glutamine; Promocell, Heidelberg, 
Germany) to 100 μM and vortexed for 15 minutes.  The Aβ oligomers solution was then 
incubated for 24 hours at 4°C.  The polyvinylidene fluoride membranes were blocked for one 
hour at room temperature in Tris-buffered saline (TBS) (containing 0.1% Tween 20 with 5% 
nonfat dry milk) and were then incubated with primary antibodies: rabbit anti-APP C-terminus 
polyclonal antibody (pAb751/770, 1:1,000, Calbiochem, Billerica, MA), mouse monoclonal A1-
17antibody (clone 6E10, 1:2,000, Covance Research Products), or mouse monoclonal -actin 
antibody as a control (1:4,000, Sigma-Aldrich, St. Louis, MO).  Afterwards, membranes were 
incubated with anti-mouse (1:2,000, Cell Signaling Technology) or anti-rabbit (1:10,000, 
Thermo Fisher Scientific) IgG secondary antibodies conjugated with horseradish peroxidase as a 
tracer. Blots were detected with Super Signal West Femto Maximum Sensitivity Substrate 
(Thermo Fisher Scientific) and imaged with BIOMAX-MR Film (Thermo Fisher Scientific, 
Waltham, MA).  To demonstrate equal loading, membranes above were then stripped with β-
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mercaptoethanol stripping solution (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM β-
mercaptoethanol) and reprobed with mouse monoclonal antibody to -actin which allows for 
quantification of the band density ratio of Aβ to β-actin. Densitometric analysis was done as 
previously described (Tan et al., 2002a) using a FluorS Multiimager with Quantity One™ 
software (BioRad). 
 
Statistical analysis 
           For the HUCBC treatment data, western blot band density data were presented as mean ± 
SEM including behavioral analysis, Aβ burden and microgliosis for each cohort of mice. All 
data were normally distributed. For rotarod tests, data were analyzed using the repeated measures 
two-way analysis of variance (ANOVA) followed by a post hoc Bonferroni to determine the 
significant difference among the means of the groups investigated (genotype x treatment).  For 
the RAWM behavior tests the repeated-measure ANOVA followed by the post-hoc Fisher’s 
Least Significant Difference (LSD) analyses were performed to compare differences between 
groups.  A t-test for independent samples was used to determine the significant difference 
between HUCBC and PBS treatment groups for Aβ burden and both soluble and insoluble Aβ40, 
42 (Abeta data) and for percentage of 4G8 (microgliosis data).  
        For the HUCBC-monocyte treatment data were presented as mean ± SEM for the 
behavioral analysis for each cohort of mice. All data were normally distributed. For rotarod tests, 
data were analyzed using the one-way ANOVA followed by post-hoc analysis (Bonferroni) 
A Bonferroni post-hoc test was used to analyze statistical differences among the groups in the 
rotarod tests using 0.05 as the critical significance level.  For the RAWM behavior tests the 
repeated-measure ANOVA followed by post-hoc a Least Significant Difference (LSD) analysis 
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was performed to compare differences between groups.  Alpha levels were set at 0.05 for all 
analyses in the study.  A p value of < 0.05 was considered significant. On the graphs, * and # 
represent p < 0.05 while ** and ## represent p < 0.01. SPSS 18.0 software was used for all 
statistical data analyses.      
        Regarding the use of the repeated measures two-way ANOVA in the rotarod HUCBC data 
and the RAWM data for both HUCBC and HUCBC-monocyte studies; the data evaluated was 
based on the treatment group and genotype interactions. Briefly this evaluation conveyed 
whether there was improvement in my cohorts after the HUCBC treatment time course. In 
addition it also disclosed whether there were differences in my groups based on genotype across 
the time of the experiments. Overall and critical to the investigations of this study, observations 
were made to investigate whether some groups got better as compared to other 
groups.  Meanwhile in the HUCBC-monocyte study, the rotarod data was analyzed using one-
way ANOVA due to the fact that only treatment was compared in both WT and PSAPP mice, 
respectively in the presentation of the data. Based on the analysis, there were statistical 
differences among the groups. As such employing a post-hoc test such as the Bonferroni and the 
LSD were implemented to determine not only if there were main effects but to identify what 
were the main effects. Specifically rotarod data post hoc analyses in both the HUCBC and the 
HUCBC-monocyte studies, the Bonferroni test (tantamount to doing a series of pairwise 
comparison t-tests) was used because of its stringency in managing the multiple means of the 
study’s data. In the RAWM, for both the HUCBC and the HUCBC-monocyte studies, the LSD 
was used as post hoc analysis due to its low risk method of multiple-group differences analysis 
for a true positive and its strength with narrow confidence levels.  
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        Two limitations of the study were (1) the controls were relatively smaller as compared to 
the treated groups; and (2) the constraint of the lengthy time points that restricted the 
introduction of new cohorts. It was decided to utilize the available wild type cohorts rather than 
not include them in the experiment to obtain information on possible trends emanating from the 
study.   
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CHAPTER THREE 
 
Bio-distribution of infused human umbilical cord blood cells in Alzheimer’s disease-like 
murine model 
Introduction 
 
 Previous reports from this study and others have shown that multiple small intravenous 
administrations of HUCBCs have enormous clinical potential in that they can reduce cognitive 
impairment, Aβ levels, β-amyloid plaques, amyloidogenic APP processing, and reactive 
microgliosis in mouse models of AD (PSAPP and Tg2576 mice; Darlington et al., 2013; Giunta 
et al., 2008; Nikolic et al., 2008;). A single high dose of HUCBC treatment (1.10 x 10
7
cells) can 
even significantly extend the lifespan of AD mice overexpressing human Swedish APP695 
mutation (Ende et al., 2001). Additional studies indicate that HUCBCs improve therapeutic 
outcomes in rodent models of Parkinson’s disease (PD) (Ende et al., 2002; Song et al., 2013; Orr 
et al., 2002), amyotrophic lateral sclerosis (ALS) (Garbuzova-Davis et al., 2012), types 1 and 2 
diabetes (Ende et al., 2002a; 2004), lupus (Ende et al., 1995), traumatic brain and spinal cord 
injury (Garbuzova-Davis et al., 2006; Saporta et al., 2003 Lu et al., 2002) and stroke (Chen et al., 
2001; Vendrame et al., 2004). While the therapeutic consequence of these HUCBCs is of 
unquestionable medical merit, it is equally important to characterize which organs these cells 
migrate to and how long they maintain a presence in these tissues.  In stem cell studies, data 
obtained via in vivo real-time visualization, may be crucial to elucidating optimal administration 
methods, effective infusion time window and optimal dosage (Bok-Nam P et al., 2011).  In this 
report, we followed the bio-distribution of HUCBCs following a single intravenous treatment in 
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PSAPP mice and non-transgenic Sprague-Dawley rats. Both mice and rats were used as a guide 
of bio-distribution of these cells across species.  In vivo HUCBC distribution in tissues of rodent 
species was determined by subjecting these tissues to total DNA isolation and PCR amplification 
of the rimers specific for human glycerol-3-phosphate dehydrogenase.  Clarifying the homing 
proclivity and longevity of HUCBCs following this route of administration is useful for 
elucidating its potential effectiveness and mechanism of action in the treatment of 
neurodegenerative disorders. 
 
Results 
         In order to determine the bio-distribution of HUCBCs after a single low dose intravenous 
injection, and to understand whether pathological and/or normal, healthy conditions could induce 
HUCBC infiltration into the CNS, PSAPP mice and Sprague-Dawley rats were injected with 
HUCBCs into the tail vein at 1.0 x 10
5
 cells/100 μL for mice and 2.2 x 105 cells/100 μL for rats.  
The presence of human glycerol 3-phosphate dehydrogenase (HG3PDH) DNA in various tissues, 
determined by PCR analysis, was used as a screen to determine the distribution of HUCBCs.  
Within 24 hours after injection, HG3PDH DNA appeared in brain, spinal cord, spleen, kidney, 
liver and heart of both mice and rats (Table 3, Table 4 and Fig. 4).  While these cells were also 
present in BM, lung and gonads of both species, they were found in fewer animals. At 7 days, 
cells were observed in all organs except kidneys.  In both mice and rats HUCBCs in the kidney 
was trending to dying off as progressively fewer animals retained these cells. While cells were 
not detected in blood of either of the species after 24 hours, they were detected 7 days post 
injection and persisted to the 30 day time point, albeit it was trending to be present in fewer 
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animals as the time progressed. 30 days after treatment, these cells were found in all organs, 
albeit in fewer animals. 
 
Table 3 PSAPP double transgenic mice were given one single injection of 1 x 10
5 
HUCBCs 
via the tail vein (n=6 per group). After tissue collection, DNA isolation, and PCR 
replication of Human G3PDH, DNA was detectable in virtually all organs tested, except 
blood, 24 hours after HUCBC administration.  By 30 days, bone marrow, brain, spleen, 
kidney, liver, heart, lungs and gonads were found to contain human DNA, while only 2 
animals showed positive for HG3PDH DNA in blood and spinal cord. 
 
 
Organs/Tissues from Mice  – Tissue 
Collected 24 h, 7 or 30 days after 
HUCBC injection 
 
Presence of Human DNA 
24 Hours   
(n=6) 
7 Days       
(n=6) 
30 Days     
(n=6) 
 1) Blood 0 4 2 
 2) Bone Marrow 6 6 4 
 3) Brain  6 6 4 
 4) Spinal Cord 6 6 2 
 5) Spleen 4 6 4 
 6) Kidney 6 2 4 
 7) Liver 4 6 4 
 8) Heart 6 6 6 
 9) Lung  4 4 4 
 10) Gonads 6 4 4 
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Table 4 Non-transgenic Sprague Dawley rats were given a single injection of 2.2 x 10
5
 HUCBCs 
via the tail vein (n=6 per group).  Twenty-four hours after injection human DNA was detectable 
in virtually all animals in brain, spinal cord, spleen, kidney, liver, and heart, and also detected in 
a few animals in BM, lung and gonads, but not in blood.  By 30 days, human DNA was found in 
all organs, albeit in fewer animals, but most animals showed a similar retention of human DNA 
in their spleens.  
Organs/Tissues from Sprague Dawley 
Rats – Tissue Collected 24 h, 7 or 30 
days after injection 
Presence of Human DNA 
24 Hours   
(n=6) 
7 Days       
(n=6) 
30 Days     
(n=6) 
1) Blood 0 4 1 
2) Bone Marrow 2 4 2 
3) Brain  5 4 2 
4) Spinal Cord 6 4 2 
5) Spleen 6 6 4 
6) Kidney 5 2 2 
7) Liver 6 6 2 
8) Heart 6 5 5 
9) Lung  2 4 3 
10) Gonads 2 4 4 
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Fig. 4 Agarose gel electrophoresis of HG3PDH PCR reaction of mice organ samples, stained 
with ethidium bromide and photographed under UV light. Lane 1, denotes molecular weight 
(ladder); 100 bp marker, lanes 2-10, display organ samples as illustrated in adjacent table. 
Symbols - represents negative control and + represents positive control. 
(- = negative control, + = positive control) 
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All animals survived for the entirety of the transplantation periods.  Over all, these results 
indicate that within 24 hours after a single intravenous injection, HUCBCs can home into and 
can remain in several organs for up to 30 days, in both PSAPP mice and Sprague Dawley rats. 
More specifically, HUCBCs distribute to several organs, with an apparent proclivity to BM, 
brain, spinal cord, spleen kidney and heart in mice and to brain, spinal cord, spleen, kidney, liver 
and heart in rats.  Human genomic DNA presence in blood circulation was not reliable in both 
species as a detectable trend was not evident. Interestingly, across species, distribution in the 
spleen appeared to be most consistent as human DNA was consistently present in the majority of 
cohorts from day 1 through to completion of the experiment.  
 
Discussion 
Recent studies have shown that PSAPP mice treated from 7 months of age with infused 
bone marrow-mesenchymal stem cell (BM-MSC) suspensions biweekly for 1 month exhibited 
reduced amyloid-beta deposition and rescued memory deficits (Lee et al., 2010). Further studies 
from our laboratory indicated that multiple monthly low dose injections of HUCBCs into PSAPP 
mice reduce cognitive impairment, A levels/-amyloid plaques, amyloidogenic APP processing 
and reactive microgliosis (Darlington et al., 20013).  The PSAPP transgenic mouse model of 
amyloid-beta deposition has shown numerous benefits in characterizing the role of Aβ in 
cognitive impairment and pathogenesis in AD (Lemere et al., 2003).  In order to determine the 
bio-distribution of peripherally administered HUCBCs, and thus elucidate their mechanism of 
action, the present study determined the expression of HG3PDH DNA in several tissues after a 
single intravenous injection of 1 x 10
5
 or 2.2 x 10
5
 cells/100 μL in mice and rats, respectively.  
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Due to its importance to the efficacy of cord blood, spleen tissue from the negative control 
animals (PBS treated) was used as the negative control for the gel at each time point. Cord blood, 
representative of human genomic DNA (~100 BP) was used as a positive control. Most tissues, 
including the brain, had a rapid uptake of cells.  In PSAPP mice, while cells in some tissues, for 
example bone marrow, brain, heart and lung, persisted steadily for one week or greater, cells in 
the blood were detected at 7 days but showed a tendency to dying off as only a small number of 
animals tested positive for these cells.  Interestingly HUCBCs seemed inclined to migrate to the 
spleen. This possibly resonates with findings from other cord blood studies of brain insult that 
the spleen plays a role in immune modulation (Vendrame et al., 2006). In Sprague Dawley rats, 
while the pattern was not an exact parallel; remarkably at the 24 hour time point HUCBCs was 
not detected in the peripheral blood suggesting an afflux to the brain and other tissues.    
Interestingly, we observed a decline of HUCBC DNA in the kidney of both mice and rats at 7 
days and re-emergence of a steady low positive signal in mice at the later 30 day time point.  
This reduction and re-emergence of HUCBCs in the kidneys of mice is most likely due to the 
initial clearance or removal of HUCBCs by the kidney while the cells were still in the circulation 
(before 24 hours).  Between 24 hours and 7 days, the HUCBCs migrated from the kidneys into 
the tissues and circulation. Sometime before the 30 day time point the cells may have re-emerged 
back into circulation to migrate to a different organ, only to be filtered out of the blood by the 
kidney.  With regard to the seemingly random general migration pattern, it may be that these 
cells do not migrate deeply into tissues, or far from the sites where they extravasate from the 
vessels. If this be the case, then another possibility is that we may be detecting some artifact of 
these cells that are dying in the tissue.  As with many, if not all, cell based therapies there exists 
the possibility of cell death after administration.  Not all of the cells will survive the 
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transplantation procedure, which can cause varying amounts of HUCBCs to die.  In addition, 30 
days after administration, only a fraction of the total amount of infused HUCBCs will survive.  
In one in vitro study,  immunofluorescence microphotographs of transgenic NOD SCID (non-
obese diabetic severe combined immunodeficient) mice, using human-specific antigen against 
mitochondria (HuMi), revealed that  HUCBCs   were detected five days after low dose (1 x 10
5
 
cells) transplantation but were not observed  after 1 month (Walczak et al 2007). On the other 
hand,  in in vivo experiments done in ALS mice, immunocytochemistry for HUCBCs in vivo 
using  the mouse monoclonal antibody against human nuclei (HuNu), have shown that these cells 
are capable of migrating to and surviving in peripheral and CNS organs beyond twelve weeks 
(Garbuzova-Davis et al., 2003).  As such, these observations may be partly due to differences in 
animal models used or from the possibility of detecting artifact of HUCBCs that have died in the 
tissue of these animal models or from whether experiments were conducted in vitro versus in 
vivo settings.  
The actual number of cells that reach each tissue was not ascertained, but would be 
different for either animal model used.  A greater number of HUCBCs would be found in tissues 
such as the spleen, brain and possibly spinal cord of these PSAPP mice due to the presence of 
inflammation and neurodegeneration.  The Sprague-Dawley Rats would have a more even 
distribution of HUCBCs after injection due to the lack of endogenous inflammatory stimuli and 
chemo-attractants.  HUCBCs, unlike regular pharmacological based treatment using drugs or 
other compounds, are living cells and as such are not predictive in terms of homing proclivity to 
a particular target organ or eventual anatomical localization.  Based on the different chemo-
attractant and other signals that may be found in different parts of the body in a disease state, 
these cells may home into those areas, or into other areas/organs that they may encounter.  The 
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mechanism of cell migration into the organs or why they may disappear from organs after a 
period of time is not entirely known.  These cells do not merely home to their receptor and 
activate a signaling cascade that results in a beneficial therapeutic effect.  It is believed that in 
diseased conditions, these HUCB cells that were injected in the periphery may cross the leaky 
BBB or may migrate in response to signals from cytokines and cell surface receptors and 
antigens (Shizuo et al., 2009).  They seem to alter the activation of the endogenous immune 
system, and allow for the body to possibly repair itself.  Activation of the immune system, in a 
pro-inflammatory manner, tends to promote healing initially but can actually be detrimental if 
activated chronically (Vendrame et al., 2006).  
         Additionally, studies in stroke have shown that the spleen, functioning as a secondary 
immune organ, is a chief contributor in the inflammatory progression of the neurodegenerative 
damage seen after MCAO (Ajmo et al., 2008), and that HUCBCs may act by inhibiting the 
inflammatory effects that are caused by the spleen (Vendrame et al., 2006).  Additionally it has 
been reported that the peripheral immune response can actually cause an increase in progression 
of AD symptoms and pathology in the brain (Zhu et al., 2013).  Thirty days after the low 
HUCBC infusion, these cells were no longer detectable in the spleen, further substantiating the 
study’s global claim (Chapters 4 and 5) that multiple low-dose injections of HUCBCs are 
essential not only to prevent any possible tumor formation, but to provide the continued 
behavioral and biological therapeutic benefits that were observed in AD mice.           
                While both HUCBC and BM as resources for haematopoietic progenitor cells used to 
reconstitute blood lineages after myeloablative therapy are considered the benchmark, certain 
cell populations, like monocytes, derived from HUCBCs are unique compared to those in BM 
(Brichard et al., 2001; Hill et al., 1997; Newcomb et al., 2007).  HUCB-derived monocytes, for 
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instance, have lower cytotoxic capacity because they express less HLA-DR (Theilgaard-Monch 
et al., 2001).  Additionally, HUCBCs are less of a cost factor, less time consuming and less of a 
physical burden to patients.  Thus, while both HUCBCs and BMCs are standard, when 
considering cell therapy, HUCBCs may be considered superior.  HUCBCs can be safely 
cryopreserved and remain viable for years (Mugishima et al., 1999; Liao et al., 2011).  Apart 
from retaining a primitive ontogeny, HUCBCs have not been exposed to immunologic challenge 
thus retaining an immunologically immature phenotype (van de Ven et al., 2007).  It is also 
reported that HUCBC progenitors have as much as four times as many CD34 positive cells and 
up to an eightfold proliferative capacity compared to similar cells in bone marrow (Broxmeyer et 
al., 1995).  Moreover, these cells form larger colonies, possess higher cell-cycle rates and have 
fairly long telomere lengths confirming their immature status.  With greater availability, weak 
immunogenicity and reduced probability of arbitrating viral transmission, HUCBCs may 
represent the best alternative for cell based therapy (Lewis 2002).  
        The fate, therefore, of systemic administration of hematopoietic cells is of great 
importance when considering viable therapeutic options. In diseased conditions such as in 
models of hypoxic–ischemic brain injury (Adhami et al., 2006), when WT mice that had been 
treated with myeloablative chemotherapy were infused with BM cells from GFP+ transgenic 
mice via the tail vein and later exposed to 30 minutes of hypoxic conditions, widespread 
neuronal damage occurred and BBB integrity was compromised as observed via  Fluoro-Jade B 
(FJB) staining for neuronal degeneration and by staining for immunoglobulin G (Lampron et al., 
2013).  After this initial injury, a series of inflammatory molecular and cellular events occurs 
producing a cytokine milieu. There have been reports that suggested that this acute response 
have impact on both the extent of brain injury and clinical outcomes (Smith et al., 2004). In the 
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study with Lampron et al. 2013, overexpression of the chemoattractant cytokine, CCL2 was also 
detected, suggestive of a possible factor for cell recruitment.  No GFP+ BM cells associated with 
the unaffected, healthy contralateral brain hemisphere, but GFP+ BM cells migrated in as little as 
one day post injury in highest concentrations in regions that correlated with the most widespread 
neuronal death, CCL2 expression, and BBB damage such as the hippocampus, specific cortical 
regions and striatum.  This indicated that peripheral migration entry, localization and cell 
survival are regulated by chemoattratant factors.  In another stroke study involving a rat stroke 
model (Chen et al., 2001), a medium intravenous dose of HUCBCs (3 X 10
6
 cells) infused 1 or 7 
days after MCAO significantly improved the pathological condition, while a histological assay 
showed that the cells had not only migrated to the injured hemisphere but also to contralateral 
hemisphere, albeit very few in number. In addition, analysis of a locomotor test consisting of the 
rotarod motor test and the Modified Neurological Severity Score (mms) showed that there was 
improved functional recovery after treatment with HUCBCs.   
In other biodistribution studies involving models with less widespread neuronal damage 
than stroke, such as chronic neurodegeneration associated with AD, BBB damage exists, albeit 
not as extensive (Planner et al., 2010).  Lampron et al. (2013), further studied bone marrow cell 
(BMC) migration in the AD APP/PS1 mouse model.  In this approach, 7 week-old APP/PS1 
mice that had been treated with myeloablative chemotherapy were infused with BM cells from 
GFP+ transgenic mice via the tail vein and sacrificed 7 months later.  While WT littermates had 
no GFP+ BMCs in their CNS, the chimeric APP/PS1 mice exhibited widespread CNS presence 
with intense concentrations of Iba1 + staining in the hippocampus and cortical regions.  
Additionally, these GFP+ BMCs homed into close proximity to plaques which implies that Aβ 
plaques are capable of inducing the migration of BMCs into the CNS.  That study proposed that 
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although BBB damage increases its permeability to peripheral cells, entry, homing and cell 
survival are highly regulated by specific mechanisms that are yet to be completely elucidated.  
These studies highlighted migration into CNS with pathological conditions.  
          In yet another migration study, 9 week-old G93A mice (ALS model, pre-symptomatic 
stage) were treated with a low dose of 1 x 10
6
 HUCBCs via the jugular vein. They were 
sacrificed when the progression of disease symptoms reached the point of paralysis and then 
assayed for distribution of these cells into organs and immunophenotyping (Garbuzova-Davis et 
al., 2003).  HUCBCs were characterized with the human-specific marker (HuNu) and 
immunophenotype(s) were verified by double-staining for CD45, Nestin, TuJ1, and GFAP.  It 
was found that the cells mainly persisted in the blood circulation and homed into the parenchyma 
of organs.  They reported that while cells were found in all examined organs, estimated cell 
density peaked in some organs like the CNS, spleen, kidney and liver and were observed to a 
lesser degree in lungs and heart.  Additionally the HUCBC therapy delayed disease progression 
by about two weeks.  Another merit of this study was the discovery that hematopoietic cells can 
enter the CNS even when treatment begins in the presymptomatic stage of ALS.  This finding 
adds support to the current biodistribution study of this dissertation, where HUCBCs homed 
widely in various organs including the brain and spinal cord, in both AD PSAPP mice and 
healthy Sprague Dawley rats.              
         Expanding on migration studies in pathological conditions, it appears that benefits of 
HUCBC treatment seem to arise from an evoked modulation of inflammatory processes both 
peripherally and centrally (Vendrame et al., 2006).  Studies that employed the MCAO animal 
stroke model observed that the spleen is one of the primary sources of immune cells that become 
activated and migrate in response to the progression of stroke pathology (Seifert et al., 2012) 
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eventually leading to cell death in the ischemic penumbra due to chronic inflammation.  When 
HUCBCs are administered 24 hours after the ischemic MCAO event, the immune cell activation 
and migration, as well as the massive delayed cell death observed in the penumbra, can be 
prevented (Vendrame et al., 2005; Newcomb 2006).  In vitro, it was shown that the supernatant 
from cultured HUCBC promote survival of NT2 neural cells cultured under cell stress conditions 
(El-Badri et al., 2006).  Moreover it has been shown in animal studies of  traumatic brain injury 
(TBI), spinal cord injury and MCAO that HUCBC infusion after brain injury can mediate 
recovery within days (Lu et al., 2002; Saporta et al., 2003;  for review see Newman et al., 2003 
and Sanberg et al., 2005), a time period too short for re-innervation of new cells. Hence, further 
understanding of the mechanism underlying CNS entry of these newly recruited cells, as well as 
their characterization and role in the injured CNS is important. 
        Microglia—chemotactic cells, sparsely populate the brains of healthy individuals 
(Mackenzie et al., 1995), but densely populate AD brains (Itagaki et al., 1989). This increase in 
density is believed to result from aggregation, rather than proliferation of the cells (McGeer et 
al., 1989a). Microglia appears to be derived from blood monocytes (driven by their origin) 
(Hickey et al., 1988; Lawson et al., 1992 et al., 1992) and express monocyte/macrophage 
antigens. Microglia are involved in the inflammation associated with pathology in AD and move 
chemotactically in response to concentration gradients of amyloid proteins and other factors 
(Itagaki et al., 1989). While it is still controversial, it is believed that amyloid plaques association 
with microglia is a key component of brain inflammation in AD and is closely associated with 
fibrillar amyloid cores in human (Wegiel et al., 1990; Wegiel et al., 2000; Wisniewski et al., 
1989) and transgenic mouse plaques (Frautschy et al., 1998; Wegiel et al., 2001; Wegie et al., 
2003). This is also supported by in vitro studies (Frackowiak et al., 1992). The chemotactic 
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sensitivity of microglia to amyloid proteins (see review Davis et al., 1992) has been studied 
extensively.  Neuronal stress induce glial cells to produce cytokines and other inflammatory 
factors (Mrak et al., 1995 (review), 2000, and following activation, these glial cells proliferate, 
and migrate chemotactically to sites of injury, where they secrete a host of chemicals, including 
cytokines. For example, in AD, microglia produces Interleukin-1 (see review Benveniste, 1995), 
and this induces production of other cytokines, namely, IL-6, TNF-α by astrocytes and other 
cells (see review Nilsson et al., 1998). Moreover, IL-1 induces neurons and astrocytes to secrete 
more Aβ which in turn leads to deposition of amyloid fibrils (Nilsson et al., 1998). Astrocytes 
stimulated by IL-1β   (Lee et al., 1993) mainly secrete Interleukin-6 (see review Benveniste, 
1995).  Early in the development of senile plaques, heightened levels of IL-6 are observed 
(Nilsson et al., 1998). Tumor necrosis factor-α, also mainly produced by stimulated astrocytes, is 
believed to prompt apoptosis (programmed cell death), in some types of cells, and may act as a 
chemorepellent under some conditions (Chicoine et al., 1995; Venters et al., 2000).  
         Ischemic tissues in the brain express chemotactic proteins, such as monocyte 
chemoattractant protein-1 (MCP-1/JE), (Kim et al., 1996) and adhesion molecules, e.g., 
intercellular adhesion molecule (ICAM) (Zhang et al., 1995) and vascular adhesion molecule-1 
(VCAM) on endothelial cells. In acute ischemic brain (Zhang et al., 1995; Blann et al., 1999) E-
selectin, VCAM and ICAM-1, are significantly increased in microvascular endothelial cells.  
Moreover HUCBC express several adhesive-related antigens, namely integrin subunits (α4 and 
α5), integrins (αvβ3 and αvβ5), and ICAM. Notably included is a critical homing integrin; VLA4 
(α4vβ1) that is involved in mononuclear trafficking to target areas through association with 
VCAM, an inducible vascular ligand (Conget et al., 1999). It is possible that HUCBCS migration 
across the blood-brain barrier into ischemic areas is facilitated by this association. 
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         HUCBCs migrate to these areas of degeneration/inflammation (Chen et al., 2001; 
Garbuzova-Davis et al., 2003; Lu et al., Kim et al., 2002). While injected HUCBCs may 
distribute in different organs in various models of disease such as the lung, liver and kidney, it 
has been reported that in animal models of disease such as stroke, ALS, spinal cord or TBI, 
intravenously infused HUCBCs can distribute to regions of degeneration and reduce behavioral 
deficits (Chen et al., 2001; Garbuzova-Davis et al., 2003; Lu et al., Kim et al., 2002). Further, it 
also appears that that these cells have a proclivity to home to the spleen and bone marrow as can 
be correlated with data from our AD studies (Table 3 and Table 4 Fig. 4).   
        Bio-distribution data in this study showed that over time (30 days) the spleen in fewer 
animals contained cells from low dose HUCBC administration, thus corroborating the need for 
multiple low dose injections to allow for continued therapeutic benefit of those cells without the 
concern of HLA matching and the possibility of tumor formation/ ectopic cell growth. Results 
showed a relatively similar bio-distribution and retention of HUCBCs in both PSAPP mice and 
Sprague Dawley rats.  Using PCR analysis of HG3PDH DNA, HUCBCs were detected in brains 
and spinal cords of both mice and rats for up to 30 days post transplantation.  It is possible that 
these cells, while present in the CNS, may have expressed neural markers such as neural lineage 
antigens (Sanchez-Ramos et al., 2002; Zigova et al., 2002).  As such, thoughts of utilizing 
HUCBCs as alternative cell treatment for neurodegenerative disorders may be feasible.  
However, in that study, further immunocytochemical analysis is needed to determine if these 
cells transform into neural-like cells.  On the other hand, although HUCBCs have been detected 
in the brain after peripheral transplantation, it appears that the amount may not be enough to 
proffer direct therapeutic benefit in the brain (Vendrame et al., 2006) and that a more indirect 
effect of modifying the brain microenvironment, either by the releasing of trophic cytokines or 
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by decreasing inflammation, may be involved (Newman et al., 2006; Borlongan et al., 2004; 
Vendrame et al., 2005).  Outside the CNS, HUCBCs were distributed in several peripheral 
organs, including liver, kidney and bone marrow, of both species starting within 7 days and 
continuing up to 30 days post transplantation. Therefore, HUCBCs’ ability to reach and rapidly 
home into several tissues including the brain following a single intravenous treatment, suggests 
that this route can be a viable method of administration of these cells for the treatment of AD.  
What is more, using Sprague Dawley rats, this study showed that HUCBCs can also migrate into 
the CNS under healthy conditions, extending wider applications for therapeutic interventions 
before the development of neurodegenerative disorders. The differences in human DNA presence 
in tissues between the two models used in this study may simply be attributed to differences in 
animal models used.  Studies show that HUCBCs migrate to sites of injury and/or inflammation.  
The PSAPP mouse model expresses an over production of proteins that compose the amyloid-
beta plaques observed in Alzheimer’s disease.  The presence of this protein can cause 
inflammation, which HUCBCs have been known to migrate to and inhibit.  In contrast, Sprague-
Dawley rats are non-transgenic models which most likely do not have these inflammatory 
mediators/attractants.  The exact mechanism of efficacy with multiple low-dose HUCBC 
infusions in AD patients remains to be elucidated.  In addition, with growing belief that stem cell 
may utilize inflammatory signals to direct their migratory proclivity for cellular repair (Imitola et 
al., 2004), there is a need for further studies investigating which specific HUCBC cell type(s) 
and/or possible secreted factors, that are capable of modulating the neuroinflammation observed 
with AD, stroke, ALS and MS are essential.   
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CHAPTER FOUR 
Multiple low-dose infusions of HUCBCs improve cognitive impairments and reduce Aβ-
associated neuropathology in Alzheimer Mice* 
*Note to reader 
            Excerpts from these results have been previously published and use has been approved by 
the publisher.  Reprinted with permission from STEM CELLS AND DEVELOPMENT, Volume 
22, Number 3, 2013, pp. 412-421, published by Mary Ann Liebert, Inc., New Rochelle, NY. 
 
Introduction 
         Therapeutic effects of HUCBCs infusion in PSAPP mice might result from beneficial 
immune modulation in the periphery.  Previous experiments showed a reduction in Aβ levels/β-
amyloid pathology and associated astrocytosis following low-dose infusions of HUCBCs.  In 
that study (Nikolic et al., 2008), initial treatment began at 6 months of age where appreciable 
quantities of Aβ deposition can be seen and continued until 12 or 16 mo of age.  This correlated 
with early to late stages of AD.   These treatments encompassed short- and long- term 
immunotherapeutic strategies, yielding significant reductions in Aβ levels/β-amyloid pathology 
(Nikolic et al., 2008). 
 While these results were encouraging, speculation arose as to how effective were they in 
terms of behavioral function in AD transgenic models.  Building on the results of that recent 
study, we used locomotor ability and cognitive function behavior tests, rotarod and RAWM 
respectively, to characterize the effects of HUCBCs infused from 6 - 16 months of age for 
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PSAPP mice, encompassing most of their adult life and extending into old age, as an 
immunotherapeutic strategy for AD.  This study determined (1) the effect of HUCBCs on the 
immune system and its impact on AD and, (2) the influence of HUCBCs on locomotor ability 
and cognitive function.  The PSAPP mice underwent locomotor and cognitive function tests one 
week after each course of HUCBC treatment.  The data demonstrated reductions in cognitive 
impairment which correlated positively with reduced AD-like pathology. 
 
Results 
 
HUCBC infusion improves spatial working memory 
Previous work in a mouse model of stroke have shown that HUCBC infusion results in 
significant reduction in the infarct volume as well as rescue of neurological deficits associated 
with decreased pro-inflammatory cytokine production (Vendrame et al., 2004, 2006).  
Additionally, we previously found reduced parenchymal and vascularβ-amyloid deposits in AD 
mouse model (Nikolic et al, 2008).  Thus, here we sought to determine whether HUCBCs (95 - 
98% mononuclear cells) infusion could impact Aβ-associated cognitive deficits in PSAPP AD 
mouse model.  To evaluate whether HUCBC administrations between 6 and 16 months of age 
could improve cognitive capabilities and motor coordination of transgenic AD mice, PBS or 
HUCBC treated PSAPP mice and their WT littermates were assessed for coordination and visio-
spatial learning (Fig. 5 A-E).  On the following day, an open pool with a visible platform test 
was performed (data not shown).This test was used to verify that all mice were able to both see 
and climb the platform.  
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At 6 and 16 months of age, HUCBC-infused PSAPP mice exhibited a significant 
elevation in memory function as determined by the RAWM - hippocampus-dependent cognitive 
test.  Compared to PSAPP mice infused with PBS, HUCBC-treated PSAPP mice displayed 
superior cognitive ability to locate and swim to the goal arm of the maze with less errors (Fig. 
5B, 6-month treatment; Fig. 5C, 10-month treatment).  
  
  
Fig. 5A Experimental design to investigate the effects of 6 and 10 month HUCBC-treatments on 6 
and 12 months old PSAPP mice. Transgenic AD mice and their WT littermates were infused with 
PBS or HUCBC and assessed for locomotor learning and coordination and spatial learning. 
 
 
As seen treatment affected behavior performance. This finding shows that Aβ-associated 
spatial memory cognitive impairments can be rescued by infusion of HUCBCs.  The above 
results were further reinforced using the open pool platform test to assess whether the animals 
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possessed the motor skills sufficient to complete the water maze tasks.  Notably, at both 6- and 
10-month time-points, PSAPP mice treated with HUCBCs were able to perform similarly to WT 
littermates infused with PBS and also with lesser errors compared to PSAPP mice treated with 
PBS. 
 
 
 
 
 
 Fig. 5B, C HUCBC infusion reverses working memory deficits in PSAPP transgenic mice. PSAPP 
mice and WT littermates were treated with a monthly HUCBC injection of 1 x 10
5
 cell/100 µL for 6 
(B) or 10 months (C), followed by neurocognitive testing in a two-day version of the radial-arm 
water maze (RAWM) (B, C). In overall working memory performance, WT littermates/PBS, WT 
littermates/HUCBC, and PSAPP/HUCBC mice reveal significantly fewer errors than PSAPP/PBS 
mice (p < 0.05) as revealed by LSD that followed a repeated measures ANOVA.   
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HUCBC infusion enhances locomotor skills  
The rotarod test (Fig. 5 D-E) disclosed a significantly higher sustained balance for the 
HUCBC-treated PSAPP mice (Group 2) and their HUCBC-treated WT littermates (Group 4) 
versus their WT littermates (Group 3) or PSAPP mice treated with PBS (Group 4), respectively.   
 
 
 
Fig. 5D, E HUCBC infusion improves motor coordination and motor learning in PSAPP transgenic 
mice. Latency to fall times for the rotarod-motor component of behavior test in PSAPP transgenic mice 
and their WT littermates treated for 6 (D) and 10 (E) months with PBS and HUCBCs. To investigate 
motor learning and coordination, we performed accelerating rotarod tests.  For the two time-points, both 
PSAPP and their WT littermates treated with HUCBCs showed longer latencies remaining on the rod 
when compared with the PBS control groups.  A repeated measures ANOVA showed significant 
differences in rotarod performances between HUCBC-treated and untreated controls for both WT and 
PSAPP mice. This discrepancy in significance between HUCBC-infused groups and controls was 
sustained in repeated trials. Additionally in the 10 (E) month treatment, the divergence between HUCBC-
treated PSAPP mice and control PSAPP mice developed even more significance.  On the graph, * and ** 
represent p < 0.05 and p < 0.01 respectively. 
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All mice, in both time points, with the exception of the PBS-treated PSAPP animals 
(Group 1), exhibited robust increases in latencies to fall for day two versus day one with Group 1 
displaying minor increases in latency. Further, PSAPP mice infused with HUCBCs showed 
overall greater balance and coordination abilities than their WT littermates or PSAPP mice 
treated with PBS. 
 
Cerebral parenchymal β-amyloid plaques are reduced in AD transgenic mice 
peripherally infused with HUCBCs  
        Corresponding with reduced behavioral impairment, further studies were done to determine 
if HUCBC infusion could also reduce Aβ-associated pathology in PSAPP mice.  Each group was 
evaluated for both soluble and insoluble Aβ40, 42 cerebral levels by ELISA.  When compared to 
PBS-treated PSAPP mice, analyses of brain homogenates from HUCBC-treated PSAPP mice at 
both 6- and 10-month treatment groups, exhibited significantly decreased levels of both soluble 
(Fig. 6A, B) and insoluble (Fig. 6C, D) Aβ40 and Aβ42. To corroborate these findings, an 
immunoblotting (IB) analysis for soluble Aβ levels and APP proteolytic products was performed.  
We conducted an analysis of mouse brain homogenates using monoclonal A1-16 antibody 
(6E10) to analyze Aβ species and β-C-terminal fragments (β-CTF), from both the 6- and 10- 
month treated groups.  The 6E10 antibody specifically recognizes A, APP and β-CTF.  IB with 
this antibody showed hippocampal reductions in β-CTF and Aβ species in both HUCBC-infused 
PSAPP mice compared to PBS-treated mice (Fig. 6E, 6-month treatment; Fig. 6F, 10-month 
treatment).  In order to substantiate that 6E10 IB accurately reflected the quantitative change in 
Aβ protein levels in the hippocampus, the area of pyramidal cell layer immunoreactive to 6E10 
was quantified and standardized in regard to the amount of total β-actin protein.  Densitometric 
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analysis showed that HUCBC treatment significantly reduced the ratio of A to -actin.  At both 
time-points, HUCBC treatment significantly decreased Aβ species (Fig. 6G).  This reflects the 
widely accepted notion of an upregulation of Aβ40 and Aβ42 early on in AD and that this can be 
abrogated with HUCBC treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6A-D HUCBC treatment results in decreased A and increased anti-amyloidogenic APP 
processing.  Given that HUCBC treatment reverses reference memory deficits in PSAPP transgenic mice, 
we further analyzed brain homogenates from PSAPP mice treated with HUCBCs for 6- and 10-months 
using AELISA and immunoblotting analyses.  These analyses show decreased levels of both soluble (A, 
B) and insoluble (C, D) A40 and A42 in brain homogenates prepared from PSAPP/HUCBC mice in both 
6- and 10-month treatment groups when compared with PSAPP/PBS controls [n = 10 (5♀/5♂)].  A t-test 
revealed a significant difference between PBS- and HUCBC-treated mice for both soluble and insoluble 
A40, 42 [n = 10 (5♀/5♂)]. 
 
To evaluate reductions of Aβ plaques in HUCBCs infused mice brains, we performed 
immunohistochemistry using monoclonal Aβ17-24 antibody (4G8) staining.  Mouse brain sections 
from both 6- and 10-month HUCBC-treated PSAPP mice were stained with 4G8 antibody.  We 
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observed a distinct reduction of cerebral Aβ pathology as detected by 4G8 staining in HUCBC-
infused PSAPP mice.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6E-G HUCBC treatment results in and increased anti-amyloidogenic APP 
processing To confirm findings, soluble A levels and APP proteolytic processing were visualized by 
immunoblotting (IB) analysis.  A species and -CTF were analyzed in mouse brain homogenates from 
both 6-month (E) and10-month treatment groups (F) using monoclonal A1-16 antibody (6E10).  (G) 
Densitometry analysis shows the ratio of A to -actin *p < 0.05; ***p < 0.001.         
 
A marked reduction in amyloid plaques was seen in the hippocampi of both 6- and 10-
month HUBC-infused PSAPP mice compared to 6- or 10-month old PBS-infused PSAPP mice 
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(Fig. 7A).  Quantitative image analysis for the percentage of 4G8 immunoreactive plaques from 
hippocampal brain regions [mean ± SE, n = 10 (5♂/5♀ per group)] of PSAPP mice infused with 
HUCBCs and PSAPP mice peripherally infused with PBS revealed substantial differences 
between groups (Fig. 7B).  Specifically, these results suggest, in vivo, HUCBCs infusion lowers 
Aβ pathology in PSAPP mice after 6 and 10 months of treatment. 
 
Fig. 7A-B HUCBC infusion reduced -amyloid pathology in PSAPP mice.  (A) Mouse brain 
sections from PSAPP mice treated for 6- and 10-month with HUCBC were stained with anti-A17-24 
antibody (4G8: brown).  (B) Percentage of A 4G8 antibody immunoreactive plaques from hippocampus 
[mean ± SE; n = 10 (5♀/5♂ per group)] was quantified by image analysis.  A t-test for independent 
samples revealed significances between groups (**p < 0.01).  These results suggested, in vivo, HUCBC 
fusion appeared to lower -amyloid pathology in PSAPP mice following a10-month treatment. 
 
 
HUCBC infusion mitigates microgliosis in PSAPP mice 
There has been much accumulated evidence that activation of microglia is a crucial event 
mediating inflammatory responses in AD brains (Benzing et al., 1999; Bornemann et al., 2000).  
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Therefore, after Aβ pathology assessment, sections of mouse brains from PSAPP mice treated 
with HUCBC for 6- and 10- month were stained with monoclonal anti-CD45 antibody.  HUCBC 
infusion in PSAPP mice resulted in marked reduction of microgliosis (Fig. 8A) as assayed by 
monoclonal anti-CD45 antibody. After HUCBC treatment,  quantitative image analysis of CD45 
positive cells in the entorhinal cortex regions of PSAPP/HUCBC compared to PSAPP/PBS mice 
showed a striking reduction of microgliosis [mean ± SE, n = 10 (5♂/5♀ per group)], (Fig. 8B).   
 
Fig. 8A-B HUCBC infusion reduced microgliosis in PSAPP mice.  (A) Mouse brain sections 
from PSAPP mice treated with HUCBC for both 6- and 10-month were stained with anti-CD45 antibody 
(brown).  (B) Percentage of CD45 positive microglial cells from entorhinal cortex [mean ± SE; n = 10 
(5♀/5♂ per group)] was quantified by image analysis.  A t-test for independent samples revealed 
significances between groups (**P < 0.01; ***P < 0.001).  These results suggested, in vivo, HUCBC 
fusion appeared to reduce microgliosis in PSAPP mice followed by either a 6- or 10-month treatment. 
 
A t-test for independent samples confirmed that the expression of CD45 in microglia was 
significantly reduced in the hippocampi of both PSAPP/HUCBC groups compared to 
PSAPP/PBS groups. In vivo, these findings provide evidence that HUCBCs infusion for 6 or 10 
months significantly lowers microglial activation in PSAPP mice.  Collectively, these results 
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suggest that multiple low-dose infusions of HUCBCs are effective in reducing Aβ deposits, 
cognitive impairments and microgliosis.   
 
Statistical analysis 
        Western blot band density data were presented as mean ± SEM including behavioral 
analysis, Aβ burden and microgliosis for each cohort of mice. All data were normally 
distributed. For rotarod tests, data were analyzed using the repeated measures two-way analysis 
of variance (ANOVA) followed by a post hoc Bonferroni to determine the significant difference 
among the means of the groups investigated (genotype x treatment). From the data analysis, (Fig. 
5D, E), a main effect of HUCBCs treatment (for day1, F=19.3, p=0.001; for day 2, F=15.524, 
p=0.002) was observed. The effect of genotype (p=0.19 and 0.22) and the interactions between 
genotype and treatment (p=0.767 and 0.207) are not significant. For this 2X2 analysis, it was  
unnecessary to perform any further post hoc analysis. To further confirm the differences between 
groups,  a t-test was performed. For the RAWM behavior tests the repeated-measure ANOVA 
followed by the post-hoc Fisher’s Least Significant Difference (LSD) analyses were performed 
to compare differences between groups. A t-test for independent samples was used to determine 
the significant difference between HUCBC and PBS treatment groups for Aβ burden and both 
soluble and insoluble Aβ40, 42 (Abeta data) and for percentage of 4G8 (microgliosis data).  
 
DISCUSSION  
        For this work, starting at 6 months of age, animals were given monthly tail vein 
injections of either HUCBCs or PBS.  After each administration, mice underwent a 
comprehensive battery of motor and cognitive tests to investigate the efficacy of multiple low-
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dose HUCBC administrations for 6 and 12 months as an immunotherapeutic strategy for AD.  At 
12- and 16-months of age, after completion of neurocognitive analyses, mice were euthanized 
and evaluated for AD-like pathology.  At 6 months of age, appreciable Aβ deposits can be 
observed in PSAPP mice.  Though Aβ is ubiquitous in most cells of the body, its formation of 
plaques and the pathogenic chain of events contributing to neurodegeneration and dementia 
currently remains elusive.  Most interventions address one or more of the following therapeutic 
approaches: preventing oligomerization of Aβ and deposition, enhancing Aβ degradation, 
targeting Aβ neurotoxicity directly or indirectly, preventing or reducing Aβ production, and 
improving Aβ efflux from the brain into the peripheral blood plasma (Bates et al., 2009).  We 
chose to administer multiple low doses of HUCBCs based on our optimized method for 
reduction of vascular and parenchymal deposits used previously (Nikolic et al., 2008).  In 
addition, while it is likely that toxicity and other safety issues such as tumors and immunization 
problems may arise from high doses of HUCBCs; low doses may be more efficacious for 
translation to humans. 
 In AD, inflammatory responses mediated by glial cells are upregulated by Aβ plaque 
deposition and this increase is believed to mediate neuronal injury (Townsend et al., 2005; Lue et 
al., 2002; Eikelenboom et al., 2004; Rozemuller et al., 2005; Suo et al., 1998) and finally 
cognitive decline (Naert et al., 2011).  It was found that HUCBCs reduced the number of these 
cells in the brain.  As microglia are central to the inflammatory process of the disease, their 
observed reduction upon HUCBC infusion holds strong potential therapeutic value.  We and 
others previously found expression profiles of two pro-inflammatory molecules, implicated in 
dementia (Tan et al., 2002; Tan et al., 2002; Giunta et al., 2009; Giunta et al., 2010;  Town et al., 
2001).  CD40 and CD40L, both are markedly increased in and around Aβ plaques in AD patients 
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and in mouse models of the disease (Calingasan et al., 2002; Togo et al., 2000) and were reduced 
by HUCBCs infusion (Nikolic et al., 2008). 
 Indeed, our group has previously suggested that transplanted HUCBCs confer their effect 
on reducing cerebral amyloidosis by causing the host to secrete soluble anti-inflammatory factors 
(Nikolic et al., 2008).  This may act to reduce the CD40L-CD40 interaction on microglia which 
in turn, promotes Aβ microglial clearance.  This conclusion was determined from observations of 
decreased brain levels of the soluble form of CD40L in HUCBCs-infused PSAPP mice, and of 
increased Aβ phagocytosis/removal by microglia cultured in the presence of HUCBCs-infused 
PSAPP mouse sera or cultured from adult HUCBC-treated PSAPP mice (Nikolic et al, 2008).  In 
addition, our previous observations indicated that microglial CD40 ligation shifts these cells 
away from a Aβ phagocytic phenotype and toward a pro-inflammatory response (see review, 
Townsend et al., 2005; Giunta et al., 2009; Giunta et al., 2010).  Future studies designed to 
characterize specific soluble factors crucial for these therapeutic effects will be necessary to 
identify a pharmacotherapeutic target or targets. 
 In addition, previous works indicated that a direct microglial stimulation of naïve CD4+T 
cells is dampened by HUCBC-induced inhibition of microglial activation (Vendrame et al., 
2005).  This in turn will also yield less of the co-stimulatory proinflammatory molecules and 
CD40. Together, these could prevent infiltrating T cells from being activated and thus 
downregulate proinflammatory secretions (Vendrame et al., 2006; Rainsford et al., 2000). 
 HUCBC studies done in vitro have shown that these cells secrete soluble factors that have 
beneficial effects (Newman et al., 2003).  Cultured HUCBCs supernatants, for example, 
stimulate survival of neural cells and peripheral blood mononuclear cells cultured under 
conditions designed to induce cell stress and limit protein synthesis (El-Badri et al., 2006).  
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Moreover, HUCBCs have the capacity to stimulate generation of a vast array of cytokines and 
neurotrophic factors that modify inflammatory responses, including colony forming cells 
(Nakahata et al., 1982), IL-11 and thrombopoietin (Suen et al., 1994).  It has been reported that 
HUCBCs entry into the brain are not required to promote neuroprotection (Borlongan, et al., 
2004).  According to the above report, it is possible that recovery following brain injury is 
mediated through peripheral anti-inflammatory responses and this is a likely mechanism for this 
study’s results as shown by Vendrame et al., 2006.  Additionally, it has been reported that even if 
HUCBCs are detected in lesioned brains, they are few in quantity (Vendrame et al., 2004) and, 
moreover in other studies, of those cells that persisted in lesioned areas, only a few expressed 
neural markers (Chen et al., 2001). 
 On the other hand, it should be noted that after irradiation, peripheral macrophages are 
able to penetrate the brain and mitigate cerebral amyloidosis in AD mice, implying that 
hematogenously derived macrophages are efficient at phagocytosing and clearing Aβ deposits 
(Simard et al., 2006).  Nevertheless, earlier reports have shown that Aβ can also be phagocytosed 
or cleared by brain-resident microglia (Paresce et al., 1996; Paresce et al., 1997; Chung et al., 
1999).  In the current experimental paradigm, the presence of brain-infiltrating macrophages was 
not detected.  Specifically, tissues were stained for CD45 (a marker for both macrophages and 
microglia), and it was observed that in and around Aβ plaques there were process-bearing cells 
that morphologically resembled microglia.  Furthermore, vascular “cuffing” that would suggest 
the presence of infiltrating macrophages that are frequently observed in other CNS inflammatory 
conditions, such as experimental autoimmune encephalomyelitis (EAE) (Imrich et al., 2001), 
was not detected.  Also, given the difficulties inherent to distinguishing macrophages from 
microglia, and the ease of peripheral macrophages to enter into the brain, as well as changes of 
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microglial phenotype after brain injury (Priller et al., 2001), it remains possible that peripheral 
macrophages contribute to decreased cerebral amyloidosis after treatment with HUCBCs. 
         In this report, it has been demonstrated that HUCBC infusion significantly decreases 
Aβ/β-amyloid pathology in the brain parenchyma, reduces brain inflammation evidenced by 
reduction of activated microglia, and improves cognitive impairments associated with the AD-
like pathology in PSAPP mice.  Moreover it has been shown that these HUCBC-imparted 
beneficial effects, which correlate with increased brain to blood efflux of Aβ and a shift from 
pro-inflammatory Th1 to anti-inflammatory Th2 cytokines both in the brain and in the periphery, 
are similar to what was observed in previous studies after Aβ immunization (Town et al., 2002; 
Town et al., 2005a; Town et al., 2005b).  When taken together, these results provide the basis for 
a novel immunomodulatory strategy for AD using HUCBCs.  While the exact mechanism of 
efficacy of multiple low-dose HUCBC  infusions in AD patients is currently being elucidated, 
further studies investigating which HUCBC secreted factors are capable of modulating 
neuroinflammation, reducing AD-like pathology, and rescuing cognitive impairments will need 
to be explored.  
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CHAPTER FIVE 
Multiple low dose intravenous infusions of human umbilical cord blood derived monocytes 
reduce cognitive deficits in AD-like pathology  
 
Introduction  
         Granted that HUCBCs are beneficial therapeutics in this and several studies, it has been 
reported that for some malignancies, tumor cells can originate from rare stem cells, which can 
also be responsible for maintaining the tumor (Rossi et al., 2006).  Consequently, complete 
HUCBC infusions (95 - 98% mononuclear cells), could actually promote tumorigenesis in this 
manner by increasing the repertoire of potentially tumorigenic cells.  However, previous works 
have shown that monocytes, distinct from progenitor/stem cells, do not possess the capacity to 
self-renew and proliferate, therefore diminishes the potential for tumorigenesis from cell 
infusions (Aziz et al., 2009).  It is widely known that monocytes, part of the immune system, 
undertake immune surveillance and are very successful in removing dead cells and other cellular 
debris (Seta et al., 2007). Therefore, monocytes may play a crucial role in developing effective 
AD therapies.  To reduce the likelihood of tumorigenesis in our study, we modified our 
experiments such that only the CD14 positive monocyte fraction (HUCBC-derived monocytes), 
isolated from total HUCBC mononuclear fraction, was infused.  Preliminary experiments from 
this study found that these cells were essentially similar in therapeutic effects as total HUCBCs 
in eliciting an anti-inflammatory/Th2 responses and decreasing sCD40L in the CNS of PSAPP 
mice.  Furthermore, HUCBC-derived monocyte treatment markedly enhances Aβ clearance as 
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evidenced by a) decreased levels of soluble Aβ40, 42 in the CNS, and b) increased levels of the 
soluble Aβ40, 42 in the plasma of PSAPP mice. 
          It was further examined to see whether HUCBC-derived monocytes could have a more 
profound effect than total HUCBC in reduction of AD-like pathology in PSAPP mice.  
Recognizing that AD alters multiple cognitive domains, this study used locomotor and cognitive 
function tests to characterize the effects of HUCBC-derived monocytes infused in PSAPP mice 
(from 6 - 10 months of age) as an immunotherapeutic strategy for AD.  Early intervention is a 
key to effective therapeutics. As such, the mice underwent these evaluations starting one week 
after the initial HUCBC-derived monocyte treatment and continuing throughout early adulthood 
and incipient old-aged. Our data demonstrated that HUCB-derived CD14+ monocyte treatment 
increased cognitive rescue in mice with AD-like pathology.  
 
RESULTS 
 
       To evaluate whether treatment with HUCBC-derived monocytes (CD14 monocytes verified 
by flow cytometry), could improve locomotive and cognitive capabilities of transgenic AD mice, 
PSAPP mice and their WT littermates were treated with PBS, whole HUCBC (CB-W), HUCBC-
derived monocytes (CB-DM) and monocyte deficient- HUCBC (MD-CB) for 2 months and then 
assessed using rotarod , RAWM spatial learning and open pool coordination activity tests. On the 
first day of RAWM testing, all cohorts in block one trials performed alike, while starting from 
trials in block 3, PSAPP mice treated with CB-DM made increasingly fewer errors than those 
treated with PBS (Fig. 9B).  On day 1 and day 2, towards the end of each day’s test trials (blocks 
4 and 5 and blocks 8 and 10), PSAPP treated with CB-W or CB-DM significantly outperformed 
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the control group by locating the goal arm and swimming to the target without any errors 
(*p<0.05, **p<0.01 vs. PBS).      
 
 
 
 
 
 
 
Fig. 9A Experimental design to investigate the effects of 2 and 4 month HUCBC-derived monocyte 
treatments on 6 months old PSAPP mice. Transgenic AD mice and their WT littermates were infused 
with PBS, MD-CB, CB-W or CB-DM and assessed for locomotor learning and coordination and spatial 
learning 
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Fig. 9B, C Intravenous CB-DM transplantation improves working memory. (B) Number of errors  
over a 2 day time period in a RAWM by PSAPP mice  whose tail veins were  injected  weekly for 2  
months with PBS, MD-CB,  CB-W or CB-DM. Data shows average of errors made per block ( average of 
three trial) per day (total of 15 trials per day per mouse). Fewer number of errors in the CB-DM group 
indicated that after treatment, they learned faster and remembered more than PBS treated mice from trial 
2 on day1 (p < 0.05) and persisted with similar results throughout the experiment. Therefore, CB-DM 
treatment significantly rescued memory deficits when compared with PSAPP/PBS mice ( *p<0.05, 
**p<0.01 vs. PBS) (C) Number of errors over a 2 day time period in a RAWM by WT littermate mice 
whose tail veins were injected monthly for 2 months with PBS, CB-DM,  MD-CB or  CB-W.  On day one 
ANOVA with post hoc LSD showed significant differences from block 3 however on day two of testing 
WT/CB-DM treated mice displayed superior ability to locate goal arms that was significantly faster than 
WT/PBS controls. CB-DM treatment significantly rescued memory deficits when compared with 
WT/PBS mice (*p<0.05, **p<0.01 vs. PBS). 
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Fig. 9D, E CB-DM infusion enhances motor coordination and motor learning in PSAPP transgenic 
mice. To investigate motor learning and coordination, we performed accelerating rotarod tests.  Results 
show latency to fall times in PSAPP transgenic mice and their WT littermates treated for 2 months with 
PBS, CB-DM, MD-CB or CB-W. A repeated measures ANOVA  with a post-hoc Bonferroni showed 
significant differences in rotarod performances for CB-DM -treated groups when compared to the MD-
CB groups for all mice genotypes with an exception on day 2 for the PSAPP mice (*p<0.05, **p<0.01 vs. 
MD-CB). Although the MD-CB groups improved their performances with trial repetition, the significance 
between CB-DM -infused groups and controls was sustained in repeated trials.  
 
 
       PSAPP treated with PBS or MD-CB, however, performed similarly with upwards of 4 errors 
per block of trials (Fig 9B).  In the WT groups (Fig 9C), CB-DM and CB-W treated mice 
performed faster and remembered more than PBS treated WT mice (Fig 9C; blocks 4 and 8; 
*p<0.05, **p<0.01 vs. PBS). Although all groups achieved fewer errors as the trials progressed, 
95 
 
overall PSAPP and WT mice treated with MD-CB performed the worst of all groups (Fig. 9 B, 
C), while PSAPP and WT mice treated with CB-W and CB-DM made increasingly fewer errors. 
        The rotarod test disclosed significantly higher balance and coordination for both PSAPP 
mice and their WT littermates treated with CB-DM versus those treated with PBS, CB-W, or 
MD-CB, respectively.  Although all mice exhibited increased latency to fall over time, PSAPP 
mice treated with CB-DM showed overall greater latency to fall, indicating greater balance and 
coordination abilities, than PSAPP mice or WT littermates treated with PBS (Fig. 9D, E).  . In 
addition, on day 2, both PSAPP and their WT littermates treated with MD-CB performed 
significantly worse than the control PBS groups.  
        Similar results were observed after 4 months of treatment (Fig. 9F-I).  At 9.5 months of 
age, PSAPP mice treated with CB-DM steadily exhibited a significant elevation in memory 
function in the RAWM cognitive test (Fig. 9F) as evidenced by the increasingly fewer number of 
errors made as compared to PSAPP mice treated with PBS (*p < .05 and **p < .01)   This finding 
shows that Aβ-associated spatial memory cognitive impairments can be rescued by infusion of 
HUCBC-derived monocytes.  In addition, WT littermates treated with PBS performed 
significantly worse than those receiving CB-W or CB-DM, while overall, WT/MD-CB exhibited 
slowest learning (Fig. 9G).  The above results were further reinforced using the open pool 
platform swim test to assess whether the animals possessed the motor skills sufficient to 
complete the water maze tasks (data not shown).  Notably, after both 2- and 4-months treatment, 
PSAPP animals treated with CB-DM were able to outperform PSAPP/PBS control animals.  
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Fig. 9F, G CB-DM infusions reverses working memory deficits in PSAPP transgenic mice. (F) 
Number of errors  over a 2 day time period in a RAWM by PSAPP mice  whose tail veins were  injected  
weekly for 4 months with PBS, MD-CB,  CB-W or CB-DM. Data shows average of errors made per 
block ( average of three trial) per day (total of 15 trials per day). In the CB-DM-treated PSAPP mice the 
number of errors during the 60-second trial were significantly decreased compared with PSAPP/PBS 
mice (ANOVA *p < .05 and **p < .01 compared with PBS-treated mice). (G)For the WT littermates, 4 
month treatment with CB-DM made fewer errors than those in the PBS control group (*p < .05 and **p < 
0.01).  
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Fig. 9H, I CB-DM infusion improves motor coordination and motor learning in PSAPP transgenic 
mice—4 mo treatment. Latency to fall times for the rotarod-motor component of behavior test in PSAPP 
transgenic mice and their WT littermates treated for 4 months with PBS, CB-DM, MD-CB or CB-W.  
Cohorts treated with CB-DM in both PSAPP and their WT littermate groups displayed longer rotarod 
retention times than those cohorts treated with PBS.  A repeated measures ANOVA showed significant 
differences in rotarod performances between CB-DM -treated groups when compared with the PBS 
control groups (*p<0.05, **p<0.01 vs. PBS). This significant difference reflected a similar trend on both 
day 1 and day 2. 
 
 
Following that trend, WT/CB-DM treated mice also out performed WT/PBS mice at both time 
points.  
        At four months into treatment, the rotarod test revealed that PSAPP mice treated with CB-
DM steadily increased coordination and reached the point of staying on the rod for the entire trial 
 
98 
 
time of 5 minutes (Fig. 9H; day 2) compared to their PBS treated counterparts that remained on 
the rod only half as long (*p<0.05, **p<0.01 vs. PBS).   Significantly little motor coordination and 
motor learning was observed in PBS treated WT mice as compared to their WT/CB-DM 
equivalents (Fig. 9I) (*p<0.05, **p<0.01 vs. PBS).   While all cohorts were able to learn the task 
increasingly better from day 1 to day 2, PSAPP mice treated with CB-DM performed best (Fig. 
H).   
 
Statistical analysis 
        Treatment data were presented as mean ± SEM for the behavioral analysis for each cohort 
of mice. All data were normally distributed. For rotarod tests, data were analyzed using the one-
way ANOVA followed by post-hoc analysis (Bonferroni) A Bonferroni post-hoc test was used to 
analyze statistical differences among the groups in the rotarod tests using 0.05 as the critical 
significance level.  For the RAWM behavior tests the repeated-measure ANOVA followed by 
post-hoc LSD analysis was performed to compare differences between groups.  Alpha levels 
were set at 0.05 for all analyses in the study.  A p value of < 0.05 was considered significant. 
SPSS 18.0 software was used for all statistical data analyses.      
 
Discussion 
        We have shown that HUCBC-MNCs reduce amyloid burden and microgliosis while 
markedly rescuing cognitive deficits (Nikolic et al., 2008; Darlington et al., 2013), yet it is not 
entirely certain which of the immune MNC population should be credited with promoting these 
beneficial effects.  Flow cytometry analysis of HUCBC-MNC revealed that the cellular 
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components were comprised of over 75% lymphocytes (T-cells and B-cells) and approximately 
20% monocytes (Pranke et al., 2001).  Less than 1% of the cells were immature CD34+.  
One concern we had regarding adverse effects of HUCBC-MNC infusions was the 
possibility of tumorigenesis (Rossi et al., 2006). However, previous works showed that 
monocytes do not possess the capacity to self-renew and proliferate, thus diminishing the 
potential for tumorigenesis from cell infusions (Aziz et al., 2009). Moreover studies show that 
when stimulated with granulocyte and macrophage colony stimulating factor (GM-CSF), 
interleukin (IL)-4 (Liu et al., 2001) or hepatocyte growth factor (Jiang et al., 2001a, 2001b); 
compared to adult monocytes, not only were HUCBC-derived monocytes less responsive but 
they also secreted less TNF-α, adhesion molecules and IL-1β (Jiang et al., 2001a; Le et al., 1997; 
Brichard et al., 2001).  
With this safety (Aziz et al., 2009; Jiang et al., 2001a, 2001b; Le et al., 1997; Brichard et 
al., 2001) and efficacy data (Nikolic et al., 2008; Darlington et al., 2013) obtained, we 
intravenously (i.v.) injected HUCBC-derived monocytes to determine whether these cells could 
have a more profound effect on improving locomotive and cognitive function as well as 
reduction of AD-like pathology and in PSAPP mice compared to whole HUCBC (CB-W). We 
injected PBS, whole HUCBC (CB-W), HUCBC-derived monocytes (CB-DM), and monocyte 
deficient-HUCBC (MD-CB) into PSAPP mice and their WT littermates for 2 months.   
        One limitation of the study was that the sample size of the control animals was very small. 
We nevertheless decided to under-power these wild type littermates rather than not include them 
in the study. In future studies, however, to derive increased power of our statistical test and to 
ensure that a large enough sample size is selected, a priori power analysis would be performed 
using software programs like optimal design or G Power. As such prior to conducting the study, 
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our experimental design would take into account the planned statistical test, and the values of the 
alpha (set to 0.05), the effect size expected and the planned size of our sample. If the power 
generated after these values are evaluated is less than 0.8 then the sample size would be adjusted 
accordingly. 
After 2 months of treatment coordination was assessed in these mice using the rotarod 
test and spatial memory using the radial arm water maze (RAWM) tests respectively.  Regarding 
the former, all mice exhibited increased latency to fall over time.  The rotarod test also revealed 
significantly longer balance and coordination for PSAPP mice treated with CB-DM versus those 
treated with PBS. In general, CB-DM injected PSAPP mice showed greater balance and 
coordination abilities than PBS, CB-W or MD-CB injected PSAPP mice. In the RAWM, PSAPP 
mice treated with CB-W or CB-DM made increasingly fewer errors than those treated with PBS 
or MD-CB. Though all groups achieved fewer errors as the trials progressed, overall PSAPP 
mice treated with PBS performed the worst of all groups.  
Four months into treatment, comparable results were observed in both rotarod and 
RAWM tests.  That is, CB-DM treated PSAPP mice stayed on the rod for longer times as 
compared to all other PSAPP treatment groups.   Specifically, PSAPP mice treated with CB-DM 
stayed on the rod for increasingly longer times eventually all the way up to the entire trial time of 
5 min. suggesting increased ability to coordinate balance.  In spite of all cohorts learning the task 
increasingly better from day 1 to day 2, PSAPP mice treated with CB-DM showed the greatest 
improvement compared to PSAPP mice subjected to PBS and other treatments. In the RAWM, 
when compared to all other PSAPP treatment groups, PSAPP mice treated with CB-DM 
displayed superior cognitive ability as evidenced by their ability to locate and swim to the goal 
arm of the maze with lesser errors.  
101 
 
These results were further reinforced using the open pool platform swim test to assess 
whether the animals possessed the motor skills sufficient to complete the water maze tasks.  
During both 2- and 4-months experiments, CB-DM injected PSAPP mice out performed control  
PSAPP animals (PBS) showing that more learning occurred in PSAPP mice infused with 
HUCBC-derived monocytes. 
Although not the major presenting symptoms, AD may also  lead to motor deficits such 
as ataxia and apraxia (Chainay et al., 2006; Derouesné et al., 2000; Della et al., 2004; Herbert et 
al., 2010; Buchman et al., 2011; Anheim et al., 2007).  This suggests that not only should 
cognitive impairments be investigated but also motor deficits. Our data show that Aβ-associated 
balance coordination deficits and spatial memory cognitive impairments can be rescued by 
infusion of HUCBC-DM and that these improvements were significant versus HUCBC-MNC.   
Studies in other models have confirmed our findings of the beneficial effects of HUCBC-
derived monocytes.  Recently it was reported that HUCBC-derived monocytes were necessary 
for the neuroprotection observed in a middle cerebral artery occlusion (MCAO) model of stroke 
(Womble et al., 2014).  In brief, various cell types were depleted from HUCB-MNCs in order to 
identify which could be credited with the HUCB-MNC mediated decreased infarct volume and 
enhance behavioral recovery.  Forty-eight hours after MCAO, i.v. infusions of HUCB-MNC 
preparations depleted of either CD14+ monocytes, CD133+ stem cells, CD2+ T-cells or CD19+ 
B cells were applied to male Sprague Dawley rats.  It was found that monocyte depletion 
prevented HUCBCs from reducing infarct and promoting functional recovery. Similar 
observations were reported in untreated, MCAO subjected animals.  Further, their results showed 
that CD14+ monocytes depleted from HUCBC-MNCs reversed the behavioral improvements 
that were observed with the HUCBC-MNC infusion.  Conversely, analysis of animals in the 
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group that received enriched fractions of CD14+ cells showed decreased infarct volume that 
paralleled those treated with HUCBC-MNC, suggesting this fraction of HUBC was responsible 
for therapeutic benefits. In another study (Ji et al., 2013); twenty-four hours after an hypoxia-
ischemia (HI) brain insult, neonatal Sprague-Dawley rats were i.v. injected with either HUCBC-
derived monocytes or PBS. They were assayed by erythropoietin/4', 6-diamidino-2-phenylindole 
(EPO/DAPI) and NG2/DAPI immunofluorescence double staining 7 days later.  Erythropoietin 
is a red blood cell precursor cytokine while NG2 is an oligodendrocyte precursor cell marker.  It 
was found that the rats in the HUCBC-derived monocyte group had lower levels of 
NG2+DAPI+(P<0.05) than those in the HI/HUCBC-derived monocyte group (P<0.01).  Further, 
analysis showed that whereas there more NG2+DAPI+ and EPO+DAPI+ cells in the 
HI/HUCBC-derived monocyte group, their NG2+DAPI+ cell count correlated with that of the 
EPO+DAPI+ cells (r=0.898, β=1.4604, P<0.01).  This suggests that in neonatal Sprague-Dawley 
rats, HUCBC-derived monocyte may enhance oligodendrocyte progenitor cell expression which 
in turn, is associated with elevated in EPO protein that consequently generates mechanisms for 
repair of brain white matter in hypoxic-ischemic brain damage conditions.  
        From a clinical perspective, if infusion of this one cell type can recapitulate the effect of 
total mononuclear HUCBCs, using these cells in neurodegenerative therapies may advance the 
field in a significant way.  Further it may obviate the need to inject cells which may not have a 
significant therapeutic function, thereby decreasing the risk of side effects. When taken together; 
our results provide the basis for a novel immunomodulatory strategy for AD using HUCBC-
derived monocytes.  
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CHAPTER SIX 
Discussion    
HUCBC modulation 
Tissue uptake of HUCBCs 
 While the two pervading pathological hallmarks of AD are amyloid plaques and 
hyperphosphorylated tau NFTs, the Aβ peptide appears to play a pivotal role in AD pathogenesis 
(Hardy et al.,, 1991; Selkoe et al., 2001). The Alzheimer's cascade hypothesis, one of the most 
widely accepted theories for the cause of AD, implicates tau as being downstream in the 
Alzheimer's cascade (Hardy et al., 1992; McGeer et al., 2013).  As such, although tau plays a big 
role in the pathology, studies subscribing to the tenets of the amyloid hypothesis have placed 
much emphasis on the upstream targeting of amyloid-β rather than on tau and other factors.  The 
disparity between the production and the elimination of amyloid-β has triggered a plethora of 
studies including the use of HUCB as a therapeutic intervention. The first HUCB transplant was 
done over two decades ago on a Fanconi anemia patient (Gluckmanet al., 1989) and the number 
of HUCB transplants continues grow. Further, HUCBC therapy has evolved into successful 
treatments of thousands of patients, for example in  Faconi’s anemia ( for review see Forostyak 
et al 2013) and in animal models with various diseases, including stroke, ALS and spinal cord 
injury (Garbuzova-Davis et al. 2006; Willing et al., 2003; Saporta et al., 2003; Lu et al., 1996).  
HUCBCs, are rich in hematopoietic progenitor/stem cells (Todaro et al., 2000; Mayany et al., 
1998) and have emerged as effective and relatively safe immunomodulators and neuroprotectors.  
In this regard, HUCBCs have been proven effective in reducing behavioral impairment in animal 
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models of AD and other diseases such as MI (Nikolic et al., 2008; Henning et al., 2006).  While 
this is so, it was still yet unknown as to which organ(s) HUCBCs homed to when infused in 
models of AD as well as the length of time it took for those cells to reach the organs and once 
there, how long they persisted. Furthermore, while studies have suggested maximum optimal 
dosage for HUCBCs in various diseases (Nikolic et al., 2008) and that HUCBCs are 
therapeutically beneficial in AD models (Nikolic et al., 2008), evidence on how HUCBCs might 
reduce deficits in learning and memory in AD had not been reported. The experiments in this 
study endeavored to unearth critical answers to these questions. 
 Apart from yielding valuable insights into how cell migration might be targeted to 
lesions, migration rate and the period of cell persistence in particular organs, evaluating the 
biodistribution of HUCBCs in various models of disease may also translate into predictions of 
likely therapeutic windows, optimal dosage, probable side effects and cell growth monitoring in 
human clinical trials and treatments.  While HUCBCs appeared to have therapeutic benefits, 
questions reflecting homing capabilities and longevity of these cells in animal models of AD, 
while yet unanswered, were of importance to this study.  Therefore, Chapter 3 followed the bio-
distribution of HUCBCs in AD-like transgenic PSAPP mice.  The biodistribution of HUCBCs 
was also determined for non-transgenic Sprague-Dawley rats since pre-clinical regulations 
require that treatments be administered across species for comparative evaluations.  In addition, 
apart from being widely cited in scientific literature, non-transgenic Sprague-Dawley rats are 
generally well recognized in recapitulative studies of human pharmacology, toxicology, 
reproduction and behavior research (Krinke 2000). Moreover, findings in rats showed that 
peripheral administrations of HUCBCs can enter the CNS in a non-injury disorder and this 
increases prospects for therapeutic interventions in other neurodegenerative disorders.  The 
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PSAPP transgenic mouse model of amyloid-β deposition (Wang et al., 2012, Holcomb et al., 
1998, Holcomb et al., 1999) has shown numerous benefits in characterizing the role of Aβ in 
cognitive impairment and pathogenesis in AD (Lemere et al., 2003).  This mouse model was 
selected for current experiments because of its ability to recapitulate key age and AD stage 
amyloid pathology, memory dysfunction and behavioral changes (Lemere et al., 2003).  Previous 
studies have shown that PSAPP mice treated from 7 months of age with infused bone marrow-
mesenchymal stem cell (BM-MSC) suspensions biweekly for 1 month exhibited reduced 
amyloid-β deposition and rescued memory deficits (Lee et al., 2010).   
In the current study, HUCBCs were injected into tail veins of mice or rats at a single dose 
of 1 x 10
5
 or 2.2 x 10
5 
cells, respectively, prior to harvesting of tissues at 24 hours, 7 days, and 
30 days after injection.  For determination of HUCBC distribution, tissues from both species 
were subjected to total DNA isolation and PCR amplification of the gene for human glycerol-3-
phosphate dehydrogenase.  While the results did not exhibit exact matches for mice and rat 
distributions, interestingly HUCBCs seemed inclined to migrate to the spleen in both species. 
This finding is supported by other cord blood studies of brain insult and may serve as ground 
work for future studies as the spleen has been reported to play a role in immune modulation 
(Vendrame et al., 2006). After a single intravenous treatment HUCBCs were broadly detected 
both in the brain and several peripheral organs, including liver, kidney and bone marrow of both 
species starting within 1 day and continuing up to 30 days post transplantation.  The results 
indicate that this route of administration can be sufficient to have a direct therapeutic effect in 
several tissues including the brain for up to one month after administration. What is more, by day 
30, the number of mice and rat testing positive for human DNA in their spleens decreased. It is 
possible that like in other studies of brain insult, monocytes observed at the earlier time points in 
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the spleen might have migrated to the brain in response to chemotactic cues. Additionally, in 
stroke studies, as early as 18 h post MCAO, monocytes have been observed in the brain (Stevens 
et al., 2002) and this is consistent with observation of splenic monocytes in the brain at 48 and 96 
h post MCAO. Studies show that the spleen transiently contracts in rats from 24-72 h post 
MCAO (Vendrame et al., 2006; Ajmo et al., 2008). From this contraction an increase in 
circulating splenocytes that corresponds to a decreased spleen size has been observed. What is 
more, this finding is consistent with data on splenic contraction preceding increased levels of 
peripheral white and red blood cells (Bakovic et al. 2005). This reiterates that the spleen is a 
reservoir of undifferentiated non-tissue specific monocytes (Swirski et al., 2009). While the 
exact role of the splenic response in mediating inflammation post brain injury is not entirely 
understood, removal of the spleen reduces the amount of circulating immune cells in the brain 
compared to sham MCAO animal (Ajmo et al., 2008). Therefore the intact spleen contributes to 
peripheral immune cells in the brain and with further effective and specific modulation might be 
a promising pharmacological target approach that may open the door to clinical therapies leading 
to improved AD and other neurodegenerative outcomes.   
         Historically, given the abundance of progenitor cells, it was believed that the migration of 
HUCBCs and its subsequent differentiation contributed to cell replacement which in turn 
conferred functional recovery in disease models.  Conversely, immunohistological evidence in 
stroke studies showed that the survival of transplanted HUCBCs in the CNS is relegated to mere 
insignificant numbers (Vendrame et al., 2004).  Moreover, in other reports, it was found that of 
the few cells that survived, neural markers were expressed on only a few of the survivor 
HUCBCs (Chen et al., 2001).  Therefore the HUCBCs ability to cross the BBB, proliferate and 
differentiate in sufficient amounts needed to replace lost cells was not plausible.  Furthermore, 
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and consistent with other stroke studies (Vendrame et al., 2005), it is believed that functional 
recovery may arise from suppressing the inflammatory response.  Studies have proposed that in 
stroke, the neuroinflammatory suppressed state was induced by a modulation of the immune 
system. However the exact mechanisms of how these chemokines are involved in HUCBC 
homing (Newman et al., 2006) and the ensuing beneficial effects seen in various studies have not 
been clearly delineated.  
 
Immunomodulation by HUCBCs 
 Cognitive degeneration (Lee et al., 2012; Koyama et al., 2012) has been associated with 
the long and the most toxic isoform of Aβ, Aβ42, and  this isoform has also be shown to elicit a 
strong pro-inflammatory immunological response in the brain (Simard et al., 2006). Moreover, it 
has been shown that while Aβ peptides mediate pro-inflammatory and neurodegenerative 
changes, the oligomeric forms of the peptide are neurotoxic as well as synapse toxic (Malinin et 
al., 2005).  Indeed, it is well established that brain inflammatory mechanisms mediated by 
reactive glia are activated in response to Aβ plaques (Christie et al., 2001; Eikelenboom et al., 
2004; Rozemuller et al., 2005) and these changes could negatively affect cognitive function.  
Modulation of inflammatory responses by diverse strategies including Aβ immunization, 
nonsteroidal anti-inflammatory drugs (NSAIDs), and manipulation of microglial activation states 
have been shown to reduce AD-like pathology and cognitive deficits in AD transgenic mouse 
models.  Studies suggest that HUCBCs may also function in this therapeutic capacity due to their 
unique immunomodulatory potential (Vendrame et al., 2006).  
 Preliminary experiments from this study and others showed that HUCBC infusion could 
impact Aβ-associated pathology in PSAPP mice (Nikolic et al., 2008; DeMattos et al., 2002). 
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Previously,  multiple low dose intravenous HUCBC injections have been shown to produce a 
decrease in AD-like pathology in PSAPP and Tg2576 mice characterized by significant 
reductions in: a) microgliosis, b) astrocytosis, c) CNS Aβ/β-amyloid burden, and d) cerebral 
amyloid angiopathy (CAA) (Nikolic et al., 2008).  While these findings suggests a potentially 
effective therapeutic AD intervention, there have been reports that ataxia and apraxia (Chainay et 
al., 2006; Derouesné et al., 2000; Della et al., 2004; Herbert et al., 2010) , while not a major 
symptom (Buchman et al., 2013; Anheim et al., 2007), also exist in AD. In addition, the ability 
of HUCBCs to reduce cognitive impairment had not been fully investigated. On this basis, 
Chapter 4 extended the aforementioned findings by examining the effects of monthly peripheral 
HUCBC infusion (1 x 10
5
 cell/100 µL) into the transgenic PSAPP mouse model from 6 - 16 
months of age.  Cognition and locomotor ability were examined via a two-day version of the 
RAWM, and the rotarod test respectively, followed by a subsequent observation in an open pool 
platform test.  This study showed that HUCBC therapy decreased: (1) cognitive impairment, (2) 
Aβ levels/β-amyloid plaques, (3) amyloidogenic APP processing, and (4) reactive microgliosis 
after a treatment of 6- or 10 months.  As such, this report lays the groundwork for a HUCBC 
therapy as potentially novel alternative to oppose AD at the disease-modifying level.    
 
 Cognitive rescue by HUCB-derived monocytes 
 Building on the previous findings that multiple low dose intravenous HUCBC injections 
produced a decrease in AD-like pathology in PSAPP and Tg2576  mice (Nikolic et al.,2008), 
current experiments have further shown that HUCBC multiple low-dose infusions of HUCBCs 
reduce cognitive impairments and Aβ-associated neuropathology in PSAPP mice (Chapter 4, 
Darlington et al., 2013).  Although  HUCBCs  have proven to have therapeutic benefits in AD 
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and other degenerative diseases,  HUCBCs consist of less that 1%  stem cells, and more broadly 
functionally defined as self-renewing and multipotent, generating the mature cell types of a 
particular target tissue through differentiation (Collins et al., 2005).  Aberrant self-renewal may 
parallel tumorigenesis due to uncontrolled growth.  Indeed, there is now increasing evidence in 
some malignancies that the tumor cells are organized as a hierarchy originating from rare stem 
cells with indefinite potential for self-renewal that are responsible for maintaining the tumor 
(Reya et al., 2001).  Consequently, the infusion of complete HUCBCs could actually stimulate 
tumorigenesis by increasing the repertoire of potential tumorigenic cells.   
To reduce the likelihood of tumorigenesis, this study further thought to optimize the 
system such that only HUCB-derived monocytes were infused into PSAPP transgenic mice 
(Chapter 5).   Studies have shown that not only are monocytes capable of crossing the BBB, but 
it is believed that in AD, these monocytes also play a role in amyloid plaque clearance, either by 
inhibiting its aggregation or by decreasing existing plaques (Lesbon et al., 2010 Malm et al., 
2005).  Therefore, the CD14+ monocyte fraction was infused intravenously, as multiple low 
doses (1 x 10
5
 cell/100 µL) into 6 month-old PSAPP mice.  As mentioned elsewhere, apart from 
learning and memory deficits, ataxia may also exist.  Therefore, locomotor ability and cognition 
were investigated using the rotarod test and the RAWM, respectively, followed by a swim test 
for visual acuity to confirm that any observed deficits found in the cohorts in the hidden platform 
task were not derived from sensory impairments or deficiencies in motor performance.  The data 
demonstrated that while HUCB-derived monocytes appear to be therapeutically similar to 
HUCBCs, these cells significantly increased cognitive rescue in mice with AD-like pathology 
compared to their PSAPP counterparts and wild type littermates treated with PBS.  
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Conclusion and future direction 
         In conclusion, this study demonstrated that a single low dose of HUCBCs can be 
sufficient in promoting therapeutic benefits. However, due to the low dose of HUCBCs 
administered and eventual loss of these cells in key organs, such as the spleen, the use of 
multiple low-dose infusions may be necessary to prolong the therapeutic benefit of these cells 
(Darlington et al, 2013), while still benefiting from a lower chance of ectopic cell growth.  The 
exact mechanism of efficacy with multiple low-dose HUCBC infusions in AD patients remains 
to be elucidated.  In addition, further studies investigating other HUCBC cell type(s) and/or 
possible secreted factors, that are capable of modulating the neuroinflammation observed with 
AD, stroke, ALS and MS are essential. 
 The cord blood infusion experiments extended our previous findings by supplementing 
the study with a behavioral component examining locomotion and cognition via the: (1) rotarod 
test, (2) a two-day version of the radial-arm water maze test, and (3) a subsequent observation in 
an open pool platform test to characterize the effects of monthly peripheral HUCBC infusion (1 
x 10
5
 cell/µL) into the transgenic PSAPP mouse model of cerebral amyloidosis (bearing mutant 
human APP and presenilin-1 transgenes) from 6 - 12 months of age.  Following a treatment of 6- 
or 10 months, this study showed that HUCBC therapy was associated with decreased cognitive 
impairment, reduced Aβ levels/β-amyloid plaques, diminished amyloidogenic APP processing 
and lessened reactive microgliosis.  Although more research in the field is needed, and 
specifically for future experiments of this study, larger quantities of control animals are needed 
to ensure an equal number of cohorts in all groups; these results suggest HUCBC therapy may be 
a potentially novel approach to treat AD. 
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 While this and other recent studies indicate that transplants of complete human umbilical 
cord blood cells (HUCBCs) have therapeutic benefit, growing evidence suggest that the observed 
tumorigenesis in some malignancies may arise from rare stem cells sustaining the tumor.  This 
possibility was minimized by optimizing the system, infusing only human umbilical cord blood 
derived monocytes.  It was observed that while the therapeutic benefits in the PSAPP mice 
treated with HUCB-derived monocytes were comparable to those infused with whole HUCBCs, 
these mice significantly out-performed their wild type littermates in rotarod motor learning and 
coordination behavioral tasks and RAWM cognitive learning tasks.  Overall, this study reports 
HUCBCs are rapidly migrated to tissues including the brain and that multiple low-dose infusions 
of HUCBCs present therapeutic benefits in AD.  More specifically, multiple low-dose infusions 
of HUCBC-derived monocyte therapy correlate with enhanced reduction of cognitive deficits 
and amyloid pathology, indicating that the beneficial effects of HUCBCS may be assigned, in a 
large part, to the monocyte fraction. The above conclusions provide an insight into the further 
therapeutic intervention in AD with minimized adverse effects.  
        Future experiments are needed to determine if HUCBC-monocyte infusion could also 
reduce Aβ-associated pathology in PSAPP mice. In order investigate that hypothesis; an ELISA 
to assess both soluble and insoluble Aβ40, 42 cerebral levels can be used followed by 
immunoblotting (IB) analysis for soluble Aβ levels and APP proteolytic products. Reductions in 
plaque load using immunohistochemistry (IH) can also be investigated. Our study showed that 
multiple low dose intravenous infusions of human umbilical cord blood monocytes reduce 
cognitive deficits in AD-like pathology. While CD14+/CD16+   or CCR2-CX3CR1
high
 has been 
characterized as pro-inflammatory (see Chapter 1 for details), CD14+/CD16− or 
CCR2+CX3CR1
low
 is characterized as anti-inflammatory. Neither the migratory route nor the 
112 
 
mechanism mediating the entry of monocytes from the periphery into the CNS is fully known; 
therefore an understanding of which monocyte population is recruited into the AD brain is 
necessary. Moreover by directing therapy to molecules like chemokine receptors that are 
restricted to the CD14+/CD16+ monocyte subset, in the CNS, it may be possible to modulate the 
delicate balance of their function in AD and other inflammatory diseases, without offsetting the 
potential homeostatic role of the CD14+/CD16− subset in the brain. Additionally, these 
monocyte subsets may differ in revealing possibly different responses to pathogenic insults, and 
also in lectin expression. Pro-inflammatory cytokines including IL-1β, IL-2, TNFα, and IL-6 are 
upregulated in the diseased condition (Michaud et al 2013; Neuroinflammation Working Group, 
2000). It maybe that it is through chemokine recruitment, Aβ plaques can induce monocytes in 
the periphery to cross the BBB (Fiala et al., 1998). When an insult occurs in the CNS; pro and 
anti-inflammatory cytokines are released (Gimbrone 1999), and these cytokines alter BBB 
permeability, activate chemoattractants and their receptors and modify expression of cell 
adhesion molecules all of which in turn control migration of peripheral blood immune cells into 
the brain. It has been show that these HUCBC-derived monocytes imparted beneficial effects 
may correlate with increased brain-to blood efflux of Aβ and a shift from pro-inflammatory Th1 
to anti-inflammatory Th2 cytokines both in the brain and in the periphery, as seen in our 
previous studies after Aβ immunization (Town et al., 2001; Town et al., 2002; Town et al., 
2005b).  Cytokine assays can be used to determine inflammatory conditions both in normal and 
in  diseased condition prior to and after HUCBC treatments. Thus further chemokine profiling, 
possibly using HUCBC-monocyte cell cultures both with an immune challenge such as 
Concanavalin A (ConA) and without a challenge may prove informative to unraveling a 
mechanism for the observed beneficial effects in this study.  
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